RISK EVALUATION AND MITIGATION STRATEGY (REMS)

I. GOAL

The goal of the JUXTAPID REMS is to mitigate the risk of hepatotoxicity associated with the use of JUXTAPID by ensuring that:

- Prescribers are educated about the approved indication for JUXTAPID, the risk of hepatotoxicity associated with the use of JUXTAPID; and the need to monitor patients during treatment with JUXTAPID as per product labeling.
- JUXTAPID is dispensed only to patients with a clinical or laboratory diagnosis consistent with homozygous familial hypercholesterolemia (HoFH).
- Patients are informed about the risk of hepatotoxicity associated with the use of JUXTAPID and the need for baseline and periodic monitoring.

II. REMS ELEMENTS

A. Elements to Assure Safe Use

1. Healthcare Providers (HCP) who prescribe JUXTAPID must be certified.
   a. To become certified to prescribe JUXTAPID, healthcare providers must:
      i. Review the Prescribing Information for JUXTAPID.
      ii. Review the JUXTAPID REMS Program Fact Sheet.
      iii. Complete the JUXTAPID REMS Program Prescriber Training Module and successfully complete the Knowledge Assessment.
      iv. Enroll in the JUXTAPID REMS Program by completing the JUXTAPID REMS Program Prescriber Enrollment Form and submitting it to the JUXTAPID REMS Program.
b. As a condition of certification, prescribers must:

i. Review the **JUXTAPID REMS Program Patient Guide** with each patient and counsel the patient about the appropriate use and risks associated with JUXTAPID and provide the patient a copy.

ii. Complete the **JUXTAPID REMS Program Patient-Prescriber Acknowledgement Form** for each patient and submit to the JUXTAPID REMS Program Coordinating Center.

iii. Perform the following on an ongoing basis for each patient: Complete and submit a **JUXTAPID REMS Program Prescription Authorization Form** for each new JUXTAPID prescription.

c. Aegerion must:

i. Ensure that healthcare providers who prescribe JUXTAPID are certified, in accordance with the requirements described above.

ii. Provide all of the following mechanisms for healthcare providers to complete the certification process for the JUXTAPID REMS Program: email and fax.

iii. Ensure that healthcare providers are notified when they have been certified by the JUXTAPID REMS Program.

iv. Maintain a validated, secure database of healthcare providers who are certified to prescribe JUXTAPID in the JUXTAPID REMS Program.

v. Ensure that healthcare providers meet the REMS requirements and de-certify healthcare providers who do not maintain compliance with REMS requirements.

vi. Provide the **JUXTAPID REMS Program Fact Sheet**, **JUXTAPID REMS Program Prescriber Training Module**, **JUXTAPID REMS Program Patient Guide**, **JUXTAPID REMS Program Patient-Prescriber Acknowledgement Form**, **JUXTAPID REMS Program Prescription Authorization Form** and the JUXTAPID Prescribing Information to healthcare providers who (1) attempt to prescribe JUXTAPID and are not yet certified, or (2) inquire about how to become certified.

vii. Send a **REMS Letter for Healthcare Providers** within 60 calendar days of the approval of the REMS modification (01/03/2017) to certified prescribers. The letter must be accompanied by the **JUXTAPID REMS Program Fact Sheet** and the Prescribing Information. The **REMS Letter** must also be available from the JUXTAPID REMS Program Website (www.juxtapidREMSprogram.com) at the time of the mailing, remain on the website for 6 months after the mailing and can be requested from the JUXTAPID REMS Program by phone at 1-855-JUXTAPID (1-855-898-2743).

The following materials are part of the REMS and are appended:
2. **Pharmacies that dispense JUXTAPID must be certified.**

   a. To become certified to dispense JUXTAPID, pharmacies must:

      i. Designate an authorized representative to complete the certification process by submitting the completed *JUXTAPID REMS Program Pharmacy Enrollment Form* on behalf of the pharmacy.

      ii. Ensure that the authorized representative oversees implementation and compliance with the JUXTAPID REMS Program requirements by the following:

         1) Review the Prescribing Information.

         2) Review the *JUXTAPID REMS Program Fact Sheet*.

         3) Complete the *JUXTAPID REMS Program Pharmacy Training Module* and successfully complete the *Knowledge Assessment*.

         4) Ensure all relevant staff involved in the dispensing of JUXTAPID are trained on the JUXTAPID REMS Program requirements as described in the *JUXTAPID REMS Program Pharmacy Training Module* and maintain a record of training.

         5) Put processes and procedures in place to ensure the following requirements are completed prior to dispensing JUXTAPID:

            a) Verify the *JUXTAPID REMS Program Patient-Prescriber Acknowledgement Form* is completed by accessing the JUXTAPID REMS Program database or by calling the JUXTAPID REMS Program Coordinating Center for verification.

            b) Verify the prescriber is certified in the JUXTAPID REMS Program by accessing the JUXTAPID REMS Program database or by calling the JUXTAPID REMS Program Coordinating Center for verification.

            c) Verify a *JUXTAPID REMS Program Prescription Authorization Form* is received for each new JUXTAPID prescription.
b. As a condition of certification:

i. The certified pharmacy must recertify in the JUXTAPID REMS Program if a pharmacy designates a new authorized representative.

ii. Maintain documentation that all processes and procedures are in place and are being followed for the JUXTAPID REMS Program and provide upon request to Aegerion, FDA, or a third party acting on behalf of Aegerion or FDA.

iii. Comply with audits by Aegerion, FDA, or a third party acting on behalf of Aegerion or FDA to ensure that all processes and procedures are in place and are being followed for the JUXTAPID REMS Program.

iv. Provide prescription data to Aegerion.

c. Aegerion must:

i. Ensure that pharmacies that dispense JUXTAPID are certified, in accordance with the requirements described above.

ii. Provide all the following mechanisms for pharmacies to complete certification for the JUXTAPID REMS Program: email and fax.

iii. Ensure that pharmacies are notified when they have been certified by the JUXTAPID REMS Program.

iv. Ensure that certified pharmacies are provided access to a database of certified prescribers, and patients who have a completed JUXTAPID REMS Program Patient-Prescriber Acknowledgement Form.

v. Verify every 12 months that the authorized representative’s name and contact information corresponds to that of the current designated authorized representative for the certified pharmacy. If different, the pharmacy must be required to re-certify with a new authorized representative.

vi. Send a REMS Letter for Pharmacists within 60 calendar days of the approval of the REMS modification (01/03/2017). The letter must be accompanied by the JUXTAPID REMS Program Fact Sheet and the Prescribing Information.

The following materials are part of the REMS and are appended:

- JUXTAPID REMS Program Pharmacy Training Module and Knowledge Assessment
- JUXTAPID REMS Program Pharmacy Enrollment Form
- JUXTAPID REMS Letter for Pharmacists
3. **JUXTAPID** must only be dispensed to patients with evidence or other documentation of safe-use conditions.

   a. Patients/caregivers must sign a **JUXTAPID REMS Program Patient-Prescriber Acknowledgement Form** indicating that he/she has:
      
      i. Received and has read the **JUXTAPID REMS Program Patient Guide**

      ii. Received counselling from the prescriber regarding:
          
          1) the risk of hepatotoxicity
          2) periodic liver function monitoring
          3) appropriate patient selection

   b. To authorize a patient to receive JUXTAPID under the JUXTAPID REMS Program, a certified prescriber must complete a **JUXTAPID REMS Program Prescription Authorization Form** for each new JUXTAPID prescription.

   c. Aegerion must:
      
      i. Provide all of the following mechanisms for the certified prescriber to be able to submit the completed **JUXTAPID REMS Program Patient-Prescriber Acknowledgement Form** to the JUXTAPID REMS Program: fax.

      ii. Ensure that the certified pharmacies complete the verifications required under Section A.2 for patients prior to dispensing.

      iii. Ensure that the certified pharmacies are able to verify JUXTAPID is dispensed to patients only if there is evidence or other documentation that they have met the following requirements:

          1) Patient’s **JUXTAPID REMS Program Patient-Prescriber Acknowledgement Form** is completed
          2) Prescriber is certified
          3) **JUXTAPID REMS Program Prescription Authorization Form** is received for each new JUXTAPID prescription

**B. Implementation System**

1. Aegerion must ensure that JUXTAPID is only distributed to certified pharmacies by:

   a. Ensuring that wholesalers/distributors who distribute JUXTAPID comply with the program requirements for wholesalers/distributors. The wholesaler/distributor must:

       i. Put processes and procedures in place to verify, prior to distributing JUXTAPID that the pharmacies are certified.
ii. Train all relevant staff on the JUXTAPID REMS Program requirements.

iii. Comply with audits by Aegerion, FDA, or a third party acting on behalf of Aegerion or FDA to ensure that all processes and procedures are in place and are being followed for the JUXTAPID REMS Program. In addition, wholesalers/distributors must maintain documentation to support that all processes and procedures are in place, are being followed, and make the documentation available for audits.

iv. Provide distribution data to Aegerion to verify compliance with the JUXTAPID REMS Program.

b. Ensuring that wholesaler/distributors maintain distribution records of all shipments of JUXTAPID and provide the data to the JUXTAPID REMS Program.

2. Aegerion must monitor distribution data to ensure all the processes and procedures are in place and functioning to support the requirements of the JUXTAPID REMS Program.

3. Aegerion must audit the wholesalers/distributors within 60 calendar days after the wholesaler/distributor is authorized to ensure that all processes and procedures are in place and functioning to support the requirements of the JUXTAPID REMS Program. Corrective action must be instituted by Aegerion if noncompliance is identified.

4. Aegerion must maintain a validated, secure database of certified pharmacies and prescribers in the JUXTAPID REMS Program.

5. Aegerion must maintain a validated, secure database of patients who have a completed *JUXTAPID REMS Program Patient-Prescriber Acknowledgement Form*.

6. Aegerion must maintain records of JUXTAPID distribution and dispensing, certified prescribers, certified pharmacies, wholesalers/distributors, and patients who have a completed *Juxtapid REMS Program Patient-Prescriber Acknowledgement Form* to meet REMS requirements.

7. Aegerion must maintain a JUXTAPID REMS Program Call Center 1-85-JUXTAPID (1-855-898-2743) and the JUXTAPID REMS Program Website (www.juxtapidREMSprogram.com). The REMS Program Website must include the capability to complete the prescriber and pharmacy *Knowledge Assessments* online, the option to print the PI, Medication Guide, and JUXTAPID REMS materials. The JUXTAPID product website must include a prominent REMS-specific link to JUXTAPID REMS Program Website. The JUXTAPID REMS Program Website must not link back to the product website(s).

8. Aegerion must ensure the JUXTAPID REMS Program Website is fully operational and the REMS materials listed in or appended to the JUXTAPID REMS document are available through the JUXTAPID REMS Program Website and by calling the JUXTAPID REMS Program Call Center.

9. Aegerion must monitor on an ongoing basis the certified pharmacies to ensure the requirements of the JUXTAPID REMS Program are being met. Aegerion must institute corrective action if noncompliance is identified and decertify pharmacies that do not maintain compliance with the JUXTAPID REMS Program requirements.

10. Aegerion must maintain an ongoing annual audit plan and conduct annual audits that involves wholesalers, distributors, and pharmacies.
11. Aegerion must audit all certified pharmacies within 60 calendar days after the pharmacy is certified to ensure that all processes and procedures are in place and functioning to support the requirements of the JUXTAPID REMS Program. The certified pharmacies must also be included in Aegerion’s ongoing annual audit plan. Aegerion must institute corrective action if noncompliance is identified.

12. Aegerion must take reasonable steps to improve implementation of and compliance with the requirements in the JUXTAPID REMS Program based on monitoring and evaluation of the JUXTAPID REMS Program.

III. **Timetable for Submission of Assessments**

Aegerion must submit REMS assessments to the FDA at 6 months, 12 months, and annually from the date of the initial approval of the REMS (12/21/2012). To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 calendar days before the submission date for that assessment. Aegerion must submit each assessment so that it will be received by the FDA on or before the due date.
Appendix 1: REMS Materials

- PRESCRIBER ENROLLMENT FORM
- PRESCRIBER TRAINING MODULE AND KNOWLEDGE ASSESSMENT
- FACT SHEET
- PATIENT GUIDE
- PATIENT-PRESCRIBER ACKNOWLEDGMENT FORM
- PRESCRIPTION AUTHORIZATION FORM
- LETTER FOR HEALTHCARE PROVIDERS
- WEBSITE
- PHARMACY TRAINING MODULE AND KNOWLEDGE ASSESSMENT
- PHARMACY ENROLLMENT FORM
- LETTER FOR PHARMACISTS
JUXTAPID is only available through the JUXTAPID Risk Evaluation and Mitigation Strategy (REMS) Program.

All prescribers of JUXTAPID must become certified in the JUXTAPID REMS Program. The 3-step process for prescriber certification is outlined below.

1. **REVIEW** the JUXTAPID Prescribing Information and JUXTAPID REMS Program Fact Sheet

2. **COMPLETE** the online JUXTAPID REMS Program Prescriber Training Module and JUXTAPID REMS Program Prescriber Enrollment Form

3. **AGREE** to counsel each patient using the Patient Guide, and to complete a JUXTAPID REMS Program Patient-Prescriber Acknowledgement Form with each patient

---

**PRESCRIBER INFORMATION**

First Name: ___________________________ Middle Initial: ___________ Last Name: ___________________________

Credentials: [ ] MD [ ] DO [ ] NP [ ] PA [ ] Other (specify): ___________________________

Physician Specialty: [ ] Cardiology [ ] Endocrinology [ ] Internal Medicine [ ] Other (specify): ___________________________

Practice Type (check all that apply): [ ] Individual Practice [ ] Group Practice [ ] Hospital [ ] University (Academic) Center

Practice/Facility Name: ___________________________ Department: ___________________________

Address: ___________________________________________________________________________

City: ___________________________ State: ___________ Zip: ___________________________

Phone: ___________________________ Fax: ___________________________

Email: ___________________________ NPI #: ___________________________

---

**OFFICE CONTACT**

First Name: ___________________________ Last Name: ___________________________

Phone (if different from above): ___________________________ Fax (if different from above): ___________________________

Email: ___________________________
By signing this form, I attest that:

- I understand that JUXTAPID® (lomitapide) capsules is only available through the JUXTAPID REMS Program and that I must comply with the program requirements in order to prescribe JUXTAPID.

Use:

- I understand that JUXTAPID is only indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL-apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B) and non-high density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

- I understand that the safety and effectiveness of JUXTAPID has not been established in patients with hypercholesterolemia who do not have HoFH, including those with heterozygous familial hypercholesterolemia (HeFH).

Hepatotoxicity Risk:

- I understand that there is a risk of hepatotoxicity associated with JUXTAPID.

- I understand the Recommendations for Monitoring of Transaminases with JUXTAPID treatment:
  - Measure serum ALT, AST, alkaline phosphatase and total bilirubin before initiating therapy with JUXTAPID.
  - During the first year of treatment, liver-related laboratory tests (ALT and AST at a minimum) must be measured prior to each increase in dose or monthly, whichever comes first.
  - After the first year, these parameters should be measured at least every 3 months and before any increase in dose.

REMS Program Requirements:

- I have reviewed the JUXTAPID Prescribing Information and the JUXTAPID REMS Program Fact Sheet.

- I have completed the JUXTAPID REMS Program Prescriber Training Module including the Knowledge Assessment for Healthcare Providers.

- I agree to counsel patients on the approved indication for use in patients with HoFH, the risk of hepatotoxicity with JUXTAPID and the need for regular monitoring using the JUXTAPID REMS Patient Guide.

- I agree to complete and sign the Patient-Prescriber Acknowledgement Form with the patient.

- I agree to complete and sign the JUXTAPID REMS Prescription Authorization Form for each prescription.

- I agree that personnel from the JUXTAPID REMS Program may contact me to gather further information or resolve discrepancies or to provide other information related to JUXTAPID or the JUXTAPID REMS Program.

- I agree that Aegerion, its agents and contractors such as the pharmacy providers may contact me via phone, mail, or email to survey me on the effectiveness of the program requirements for the JUXTAPID REMS Program.

Prescriber Signature: __________________________________________ Date: ________________

Prescriber Name: __________________________________________ Phone: __________________
Note to Reviewer:

The Juxtapid Prescriber Training and Knowledge Assessment can be accessed online by clicking the link on the website. The participant will need to register to enter the training and knowledge assessment module.

Participants will be required to enter their name, practice name, city, state and zip code and NPI number. The participant’s email address will be requested, if this is not provided the participant will be able to continue.
JUXTAPID® (lomitapide)

Risk Evaluation and Mitigation Strategy (REMS) Program

PRESCRIBER TRAINING MODULE and KNOWLEDGE ASSESSMENT

This interactive tool:
• Provides an overview of the JUXTAPID REMS Program
• Discusses the risk of hepatotoxicity with JUXTAPID and the recommended hepatic monitoring requirements and dose adjustments, and
• Provides an overview of the prescriber, patient and pharmacy requirements for the JUXTAPID REMS program
To become certified to prescribe JUXTAPID all prescribers must:

- **Successfully** complete this **Prescriber Training Module & Knowledge Assessment**
- **Submit** the signed **Juxtapid REMS Program Prescriber Enrollment Form** to the JUXTAPID REMS Coordinating Center
  
  either by fax: 1-855-898-2498 or email: REMS@aegerion.com

At the end of the training module there is a Knowledge Assessment with interactive questions that you must pass. If your answer is incorrect you will be directed back to the relevant page in the materials and will be required to re-answer the question.

This prescriber training module and knowledge assessment is intended to be read in conjunction with the JUXTAPID REMS Factsheet and the JUXTAPID Prescribing Information (PI).

This program is expected to take **15-20 minutes**.
Contents

- Overview of the JUXTAPID REMS Program
- Key JUXTAPID Product Information
- JUXTAPID REMS Program Information
- Knowledge Assessment
Contents

- Overview of the JUXTAPID REMS Program
- Key JUXTAPID Product Information
- JUXTAPID REMS Program Information
- Knowledge Assessment
Overview

As there is a risk of hepatotoxicity with the use of JUXTAPID it is only available through a restricted program called the “JUXTAPID Risk Evaluation and Mitigation Strategy (REMS) Program”

The purpose of this training module is to educate healthcare professionals about the JUXTAPID REMS Program.

A Risk Evaluation and Mitigation Strategy is a strategy to manage known or potential serious risks associated with a drug product and is required by the Food and Drug Administration (FDA) for some products to ensure that the benefits of the drug outweigh its risks.
The aim of the JUXTAPID REMS Program is to **mitigate the risk of hepatotoxicity associated with the use of JUXTAPID** by ensuring that:

1. **Prescribers are educated** about:
   - the approved indication for JUXTAPID;
   - the risk of hepatotoxicity associated with the use of JUXTAPID; and
   - the need to monitor patients during treatment with JUXTAPID as per the product labeling.

2. JUXTAPID is **dispensed only to patients with a clinical or laboratory diagnosis consistent with homozygous familial hypercholesterolemia (HoFH)**

   and

3. **Patients are informed about the risk of hepatotoxicity** associated with the use of JUXTAPID and the need for baseline and periodic monitoring.
Contents

- Overview of the JUXTAPID REMS Program
- Key JUXTAPID Product Information
- JUXTAPID REMS Program Information
- Knowledge Assessment
**Indication**

JUXTAPID is only indicated as an adjunct to a low-fat diet and other lipid-lowering treatments including LDL apheresis, where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

**Limitations of Use Related to the REMS:**

- The safety and effectiveness of JUXTAPID have not been established in patients with hypercholesterolemia who do not have HoFH, including those with heterozygous familial hypercholesterolemia (HeFH).

Please see JUXTAPID full Prescribing Information for the limitations to use, and the BOXED WARNING on hepatotoxicity as included on www.juxtapidREMSprogram.com
Appropriate Patient Selection

JUXTAPID is indicated only for use in patients with HoFH.
• Patients must have a clinical or laboratory diagnosis consistent with HoFH.

Contraindications Related to the REMS:
• Moderate or severe hepatic impairment or active liver disease including unexplained persistent abnormal liver function tests.

Please see JUXTAPID full Prescribing Information as included on www.juxtapidREMSprogram.com for the full contraindications.
Boxed Warning – Hepatic Information

JUXTAPID can cause elevations in transaminases. In the JUXTAPID clinical trial, 10 (34%) of the 29 patients treated with Juxtapid had at least one elevation in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 3x upper limit of normal (ULN). There were no concomitant clinically meaningful elevations of total bilirubin, international normalized ratio (INR), or alkaline phosphatase.

JUXTAPID also increases hepatic fat, with or without concomitant increases in transaminases. The median absolute increase in hepatic fat was 6% after both 26 and 78 weeks of treatment, from 1% baseline, measured by magnetic resonance spectroscopy. Hepatic steatosis associated with JUXTAPID treatment may be a risk factor for progressive liver disease, including steatohepatitis and cirrhosis.

Measure ALT, AST, alkaline phosphatase, and total bilirubin before initiating treatment and then ALT and AST regularly as recommended. During treatment adjust dose of Juxtapid if the ALT or AST are ≥ 3x ULN. Discontinue JUXTAPID for clinical significant liver toxicity.

Please see JUXTAPID full Prescribing Information including the full BOXED WARNING as included on www.juxtapidREMSprogram.com
Risk of Hepatotoxicity: JUXTAPID can Cause Elevations in Transaminases

Elevations in transaminases (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST]) are associated with JUXTAPID. In the clinical trial, 10 (34%) of the 29 patients with HoFH had at least one elevation in ALT or AST ≥3x ULN, and 4 (14%) of the patients had at least one elevation in ALT or AST ≥5x ULN. There were no concomitant or subsequent clinically meaningful elevations in bilirubin, INR, or alkaline phosphatase.

Although cases of hepatic failure have not been reported, there is concern that JUXTAPID could induce steatohepatitis, which can progress to cirrhosis over several years.

If transaminase elevations are accompanied by clinical symptoms of liver injury, such as nausea, vomiting, abdominal pain, fever, jaundice, lethargy, flu-like symptoms, increases in bilirubin ≥ 2x ULN, or active liver disease, discontinue treatment with JUXTAPID and identify the probable cause.
Risk of Hepatotoxicity
JUXTAPID Increases Hepatic Fat

JUXTAPID increases hepatic fat, with or without concomitant increases in transaminases.

The median absolute increase in hepatic fat was 6% after both 26 and 78 weeks of treatment, from 1% baseline, measured by magnetic resonance spectroscopy. Hepatic steatosis associated with JUXTAPID treatment may be a risk factor for progressive liver disease, including steatohepatitis and cirrhosis.

Clinical data suggest that hepatic fat accumulation is reversible after stopping treatment with JUXTAPID, but whether histological sequelae remain is unknown.
Dosage & Administration

The recommended starting dose of JUXTAPID is 5 mg taken once daily (QD).

The dose should be escalated gradually based on acceptable safety and tolerability.

- After two weeks, increase the dose based on acceptable safety and tolerability to 10 mg, take once daily.
- Then, at a minimum of four week intervals, increase dose to 20 mg, 40 mg, or 60 mg daily.

<table>
<thead>
<tr>
<th>QD Dose</th>
<th>Duration of Administration Before Considering Dose Increase</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 mg</td>
<td>At least two weeks</td>
</tr>
<tr>
<td>10 mg</td>
<td>At least four weeks</td>
</tr>
<tr>
<td>20 mg</td>
<td>Maximum recommended dose</td>
</tr>
<tr>
<td>40 mg</td>
<td>Maximum recommended dose</td>
</tr>
<tr>
<td>60 mg</td>
<td>Maximum recommended dose</td>
</tr>
</tbody>
</table>
## Monitoring of transaminases

<table>
<thead>
<tr>
<th>Timing</th>
<th>Liver monitoring recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prior to initiating JUXTAPID</td>
<td>Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, and total bilirubin</td>
</tr>
<tr>
<td><strong>If abnormal,</strong> consider initiating JUXTAPID only after an appropriate workup and the baseline abnormalities have been explained or resolved.</td>
<td></td>
</tr>
<tr>
<td>During the first year of treatment</td>
<td>ALT and AST (at a minimum) prior to each increase in dose or monthly, whichever occurs first</td>
</tr>
<tr>
<td>After the first year of treatment</td>
<td>ALT and AST (at a minimum) at least every 3 months and before any increase in dose</td>
</tr>
</tbody>
</table>

**At any time during treatment**

If transaminases are abnormal, reduce or withhold dosing of JUXTAPID and monitor as recommended in the Prescribing Information. Discontinue JUXTAPID for persistent or clinically significant elevations.

If transaminase elevations are accompanied by clinical symptoms of liver injury (such as nausea, vomiting, abdominal pain, fever, jaundice, lethargy, flu-like symptoms), increases in bilirubin $\geq 2x$ ULN, or active liver disease, discontinue treatment with JUXTAPID and identify the probable cause.

Continued next slide
# Hepatic Monitoring Recommendations

*Recommendations based on an ULN of approximately 30-40 international units/L

<table>
<thead>
<tr>
<th>ALT or AST</th>
<th>Treatment and Monitoring Recommendations*</th>
</tr>
</thead>
</table>
| ≥3x and <5x ULN | - Confirm elevation with a repeat measurement within one week.  
- If confirmed, reduce the dose and obtain additional liver-related tests if not already measured (such as alkaline phosphatase, total bilirubin, and INR).  
- Repeat tests weekly and withhold dosing if there are signs of abnormal liver function (increase in bilirubin or INR), if transaminase levels rise above 5x ULN, or if transaminase levels do not fall below 3x ULN within approximately 4 weeks. In these cases of persistent or worsening abnormalities, also investigate to identify the probable cause.  
- If resuming JUXTAPID after transaminases resolve to <3x ULN, consider reducing the dose and monitor liver-related tests more frequently. |
| ≥5x ULN | - Withhold dosing, obtain additional liver-related tests if not already measured (such as alkaline phosphatase, total bilirubin, and INR), and investigate to identify the probable cause.  
- If resuming JUXTAPID after transaminases resolve to <3x ULN, reduce the dose and monitor liver-related tests more frequently. |

If transaminase elevations are accompanied by clinical symptoms of liver injury (such as nausea, vomiting, abdominal pain, fever, jaundice, lethargy, flu-like symptoms), increases in bilirubin ≥2x ULN, or active liver disease, discontinue treatment with JUXTAPID and investigate to identify the probable cause.
Contents

- Overview of the JUXTAPID REMS Program
- Key JUXTAPID Product Information
- JUXTAPID REMS Program Information
- Knowledge Assessment
The aim of the JUXTAPID REMS Program is to mitigate the risk of hepatotoxicity associated with the use of JUXTAPID by ensuring that:

1. **Prescribers are educated** about:
   - the approved indication for JUXTAPID;
   - the risk of hepatotoxicity associated with the use of JUXTAPID; and
   - the need to monitor patients during treatment with JUXTAPID as per the product labeling.

2. JUXTAPID is dispensed only to patients with a clinical or laboratory diagnosis consistent with homozygous familial hypercholesterolemia (HoFH)

   and

3. **Patients are informed** about the risk of hepatotoxicity associated with the use of JUXTAPID and the need for baseline and periodic monitoring.
Prescribers must be certified to prescribe JUXTAPID.

Patients must undergo education about the approved indication for use (HoFH) and the risk of hepatotoxicity with JUXTAPID and the need for regular monitoring as part of the REMS Program.

Pharmacies must be certified to distribute and dispense JUXTAPID.
Prescriber Certification Process

1 REVIEW the JUXTAPID
   • JUXTAPID Prescribing Information
   • JUXTAPID REMS Program Fact Sheet

2 COMPLETE the JUXTAPID REMS Program
   • Prescriber Training Module and Knowledge Assessment

3 AGREE to:
   • Counsel patients using the JUXTAPID REMS Program Patient Guide
   • Complete, sign and submit the JUXTAPID REMS Program Patient-Prescriber Acknowledgement Form with the patient
   • Submit a JUXTAPID REMS Program Prescription Authorization Form for each prescription

4 SUBMIT to the REMS Coordinating Center the:
   • Completed JUXTAPID REMS Program Prescriber Enrollment Form
1. **Certify** as a Prescriber in the JUXTAPID REMS Program*

2. **Review** Patient Guide with Patient
   - Complete & Sign Patient Prescriber Acknowledgement Form (PPAF), give copy of Patient Guide PPAF to Patient
   - Submit the PPAF to JUXTAPID REMS Program

3. **Complete & Sign the Prescription Authorization Form** (PAF)
   - Fax the PAF to the JUXTAPID REMS Program

*prescribers are only required to certify one time

JUXTAPID REMS Program:
Email: REMS@Aegerion.com
☎ 1-855-898-2743  fax: 1-855-898-2498
Where do I find the REMS Program Materials?

All JUXTAPID REMS Program materials can be found on the JUXTAPID REMS Program website:

www.juxtapidREMSprogram.com

REMS Materials can also be requested by contacting the JUXTAPID REMS Coordinating Center at:

☎ 1- 855-898-2743
Knowledge Assessment
Question 1

The goals of the JUXTAPID REMS program are:
(check the answer that is the most inclusive)

☐ To educate prescribers about the risk of hepatotoxicity with the use of JUXTAPID.
☐ To restrict the use of JUXTAPID to only those patients with a clinical and laboratory diagnosis of HoFH.
☐ To ensure both prescribers and patients understand the risk of hepatotoxicity with JUXTAPID and the need for monitoring of liver function.
☐ All of the above.
Question 1

The goals of the JUXTAPID REMS program are:
(check the answer that is the most inclusive)

- To educate prescribers about the risk of hepatotoxicity with the use of JUXTAPID.
- To restrict the use of JUXTAPID to only those patients with a clinical and laboratory diagnosis of HoFH.
- To ensure both prescribers and patients understand the risk of hepatotoxicity with JUXTAPID and the need for monitoring of liver function.
- All of the above.

Partly correct

The education of prescribers about the risk of hepatotoxicity with the use of JUXTAPID is a key part of the JUXTAPID REMS Program. However, there are other goals. Review the REMS Program goals and try again.
Question 1

The goals of the JUXTAPID REMS program are:
(check the answer that is the most inclusive)

☐ To educate prescribers about the risk of hepatotoxicity with the use of JUXTAPID.
☐ To restrict the use of JUXTAPID to only those patients with a clinical and laboratory diagnosis of HoFH.
☐ To ensure both prescribers and patients understand the risk of hepatotoxicity with JUXTAPID and the need for monitoring of liver function.
☐ All of the above.

Partly correct

The restriction of the use of JUXTAPID to patients with a clinical or laboratory diagnosis of HoFH is a key part of the JUXTAPID REMS Program. However there are other goals. Review the REMS Program goals and try again.
The goals of the JUXTAPID REMS program are:
(check the answer that is the most inclusive)

☐ To educate prescribers about the risk of hepatotoxicity with the use of JUXTAPID.
☐ To restrict the use of JUXTAPID to only those patients with a clinical and laboratory diagnosis of HoFH.
☐ To ensure both prescribers and patients understand the risk of hepatotoxicity with JUXTAPID and the need for monitoring of liver function.
☐ All of the above.

Partly correct

The education of both prescribers and patients about the risk of hepatotoxicity with JUXTAPID and the need for monitoring is an important part of the JUXTAPID REMS Program. However, there are other goals. Review the REMS Program goals and try again.
Question 1

The goals of the JUXTAPID REMS program are:
(check the answer that is the most inclusive)

☐ To educate prescribers about the risk of hepatotoxicity with the use of JUXTAPID.
☐ To restrict the use of JUXTAPID to only those patients with a clinical and laboratory diagnosis of HoFH.
☐ To ensure both prescribers and patients understand the risk of hepatotoxicity with JUXTAPID and the need for monitoring of liver function.
☐ All of the above.

Correct!
All three are goals of the JUXTAPID REMS Program.
Question 2

Which conditions are appropriate for the use of JUXTAPID?

a. Mixed dyslipidemia.
b. Homozygous familial hypercholesterolemia (HoFH).
c. Heterozygous familial hypercholesterolemia (HeFH).
d. All of the above.
Question 2

Which conditions are appropriate for the use of JUXTAPID?

a. Mixed dyslipidemia.

b. Homozygous familial hypercholesterolemia (HoFH).

c. Heterozygous familial hypercholesterolemia (HeFH).

d. All of the above.

Incorrect

JUXTAPID is indicated for use in patients with homozygous familial hypercholesterolemia (HoFH).

Review the Indication for JUXTAPID and try again.
Question 2

Which conditions are appropriate for the use of JUXTAPID?

a. Mixed dyslipidemia.
b. Homozygous familial hypercholesterolemia (HoFH).
c. Heterozygous familial hypercholesterolemia (HeFH).
d. All of the above.

Correct!

JUXTAPID is indicated for use as an adjunct to a low-fat diet and other lipid-lowering treatments including LDL apheresis, where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

Click here to advance
Question 2

Which conditions are appropriate for the use of JUXTAPID?

a. Mixed dyslipidemia.

b. Homozygous familial hypercholesterolemia (HoFH).

c. Heterozygous familial hypercholesterolemia (HeFH).

d. All of the above.

JUXTAPID is indicated for use in patients with homozygous familial hypercholesterolemia (HoFH).

Review the Indication for JUXTAPID and try again.
Question 2

Which conditions are appropriate for the use of JUXTAPID?

a. Mixed dyslipidemia.
b. Homozygous familial hypercholesterolemia (HoFH).
c. Heterozygous familial hypercholesterolemia (HeFH).
d. All of the above.

Incorrect

JUXTAPID is indicated for use in patients with homozygous familial hypercholesterolemia (HoFH).

Review the Indication for JUXTAPID and try again.
Question 3

What are the hepatic monitoring recommendations during the first year of treatment with JUXTAPID?

a. Check transaminases only if the patient experiences signs and symptoms of liver injury.

b. Monitor transaminase levels every 3 months.

c. Monitor ALT and AST (at a minimum) prior to each increase of dose or monthly, whatever occurs first.
Question 3

What are the hepatic monitoring recommendations during the first year of treatment with JUXTAPID?

a. Check transaminases only if the patient experiences signs and symptoms of liver injury.

b. Monitor transaminase levels every 3 months.

c. Monitor ALT and AST (at a minimum) prior to each increase of dose or monthly, whatever occurs first.

Incorrect
During the first year of therapy transaminases should be monitored every 30 days or prior to each increase in dose.

At a minimum ALT and AST should be checked every 30 days.

Review the Hepatic Monitoring Recommendations for JUXTAPID and try again.
Question 3

What are the hepatic monitoring recommendations during the first year of treatment with JUXTAPID?

a. Check transaminases only if the patient experiences signs and symptoms of liver injury.

b. **Monitor transaminase levels every 3 months.**

c. Monitor ALT and AST (at a minimum) prior to each increase of dose, or monthly, whichever occurs first.

Incorrect

During the first year of therapy transaminases should be monitored every 30 days or prior to each increase in dose.

At a minimum ALT and AST should be checked every 30 days.

Review the Hepatic Monitoring Recommendations for JUXTAPID and try again if **b** is chosen.
Question 3

What are the hepatic monitoring recommendations during the first year of treatment with JUXTAPID?

a. Check transaminases only if the patient experiences signs and symptoms of liver injury.
b. Monitor transaminase levels every 3 months.
c. Monitor ALT and AST (at a minimum) prior to each increase of dose or monthly, whatever occurs first.

Correct! During the first year of therapy transaminases should be monitored every 30 days or prior to each increase in dose.

At a minimum ALT and AST should be checked every 30 days.

Click here to advance
Question 4

Jane Smith is 24 years old and has a clinical and laboratory diagnosis of HoFH. She has been on JUXTAPID for 13 months, appears to be compliant with her medication. You want to increase the dose, what should you do before you increase the dose?

a. Measure AST, ALT, alkaline phosphatase and total bilirubin after the increase in dose.
b. Increase her dose, see her back in a month.
c. Measure AST, ALT, alkaline phosphatase and total bilirubin if not performed in the last 30 days and only adjust the dose if normal.
Question 4

Jane Smith is 24 years old and has a clinical and laboratory diagnosis of HoFH. She has been on JUXTAPID for 13 months, appears to be compliant with her medication. You want to increase the dose, what should you do before you increase the dose?

a. Measure AST, ALT, alkaline phosphatase and total bilirubin after the increase in dose.

b. Increase her dose, see her back in a month.

c. Measure AST, ALT, alkaline phosphatase and total bilirubin if not performed in the last 30 days and only adjust the dose if normal.

Incorrect

Before you increase Ms. Smith’s dose minimally AST and ALT should be measured and confirmed to be within acceptable ranges. Review the options and consider another approach.

Review the Hepatic Monitoring Recommendations for JUXTAPID and try again.
Question 4

Jane Smith is 24 years old and has a clinical and laboratory diagnosis of HoFH. She has been on JUXTAPID for 13 months, appears to be compliant with her medication. You want to increase the dose, what should you do before you increase the dose?

a. Measure AST, ALT, alkaline phosphatase and total bilirubin after the increase in dose.

b. Increase her dose, see her back in a month.

c. Measure AST, ALT, alkaline phosphatase and total bilirubin if not performed in the last 30 days and only adjust the dose if normal within the last 30 days.

If b is chosen

Incorrect

Before you increase Ms. Smith’s dose minimally AST and ALT should be measured and confirmed to be within acceptable ranges. Review the options and consider another approach.

Review the Hepatic Monitoring Recommendations for JUXTAPID and try again.
Question 4

Jane Smith is 24 years old and has a clinical and laboratory diagnosis of HoFH. She has been on JUXTAPID for 13 months, appears to be compliant with her medication. You want to increase the dose, what should you do before you increase the dose?

a. Measure AST, ALT, alkaline phosphatase and total bilirubin after the increase in dose.

b. Increase her dose, see her back in a month.

c. Measure AST, ALT, alkaline phosphatase and total bilirubin if not performed in the last 30 days and only adjust the dose if normal within the last 30 days.

**Correct!**

Before you increase Ms. Smith’s dose minimally AST and ALT should be measured and confirmed to be within acceptable ranges.
Question 5

Your patient Thomas Jones, who has a clinical and laboratory diagnosis of HoFH presents to your clinic after being on JUXTAPID for 6 months. His ALT is ≥ 5x the ULN.

Your next step should be:

- a. Withhold dosing, obtain additional liver related labs and investigate the potential cause.
- b. Repeat the ALT in one week, if still elevated reduce the dose, repeat ALT tests weekly until it is less than 3x ULN.
- c. Decrease the dose of JUXTAPID.
- d. Continue the JUXTAPID for another month and re-measure the ALT.
Question 5

Your patient Thomas Jones, who has a clinical and laboratory diagnosis of HoFH presents to your clinic after being on JUXTAPID for 6 months. His ALT is ≥ 5x the ULN.

Your next step should be:

a. Withhold dosing, obtain additional liver related laboratories and investigate the potential cause.

b. Repeat the ALT in one week, if still elevated reduce the dose, repeat ALT tests weekly until it is less than 3x ULN.

c. Decrease the dose of JUXTAPID.

d. Continue the JUXTAPID for another month and re-measure the ALT.

Correct!

If AST and/or ALT is ≥ 5x ULN the dose of JUXTAPID should be withheld, obtain additional liver related laboratories if not already obtained and investigate the potential cause. Withhold dosing until transaminase levels drop below 3X ULN.
Question 5

Your patient Thomas Jones, who has a clinical and laboratory diagnosis of HoFH presents to your clinic after being on JUXTAPID for 6 months. His ALT is ≥ 5x the ULN.

Your next step should be:

a. Withhold dosing, obtain additional liver related laboratories and investigate the potential cause.

b. Repeat the ALT in one week, if still elevated reduce the dose, repeat ALT tests weekly until it is less than 3x ULN.

c. Decrease the dose of JUXTAPID.

d. Continue the JUXTAPID for another month and re-measure the ALT.

Incorrect

If AST and/or ALT is ≥ 5x ULN the dose of JUXTAPID should be withheld, obtain additional liver related laboratories if not already obtained and investigate the potential cause. Withhold dosing until transaminase levels drop below 3X ULN.

Review the Hepatic Monitoring Recommendations for JUXTAPID and try again.
**Question 5**

Your patient Thomas Jones, who has a clinical and laboratory diagnosis of HoFH presents to your clinic after being on JUXTAPID for 6 months. His ALT is $\geq 5x$ the ULN.

Your next step should be:

- a. Withhold dosing, obtain additional liver related laboratories and investigate the potential cause.
- b. Repeat the ALT in one week, if still elevated reduce the dose, repeat ALT tests weekly until it is less than $3x$ ULN.
- c. **Decrease the dose of JUXTAPID.**
- d. Continue the JUXTAPID for another month and re-measure the ALT.

**Incorrect**

If AST and/or ALT is $\geq 5x$ ULN the dose of JUXTAPID should be withhold, obtain additional liver related laboratories if not already obtained and investigate the potential cause. Withhold dosing until transaminase levels drop below $3X$ ULN.

Review the [Hepatic Monitoring Recommendations](#) for JUXTAPID and try again.
Question 5

Your patient Thomas Jones, who has a clinical and laboratory diagnosis of HoFH presents to your clinic after being on JUXTAPID for 6 months. His ALT is ≥ 5x the ULN.

Your next step should be:

a. Withhold dosing, obtain additional liver related laboratories and investigate the potential cause.

b. Repeat the ALT in one week, if still elevated reduce the dose, repeat ALT tests weekly until it is less than 3x ULN.

c. Decrease the dose of JUXTAPID.

d. Continue the JUXTAPID for another month and re-measure the ALT.

If d is chosen

 Incorrect

If AST and/or ALT is ≥ 5x ULN the dose of JUXTAPID should be withheld, obtain additional liver related laboratories if not already obtained and investigate the potential cause. Withhold dosing until transaminase levels drop below 3X ULN.

Review the Hepatic Monitoring Recommendations for JUXTAPID and try again.
Question 6

Sandra Brown has been on JUXTAPID for 4 months. She presents to your clinic with nausea, vomiting, abdominal pain, jaundice and is feeling “achy all over”.

You check transaminases and the AST is 3x ULN, the ALT is 2 x ULN.

What should you do next?

b. Identify the probable cause.
c. Follow AST, ALT, total bilirubin and alkaline phosphatase until normal.
d. All of the above
Question 6

Sandra Brown has been on JUXTAPID for 4 months. She presents to your clinic with nausea, vomiting, abdominal pain, jaundice and is feeling “achy all over”.

You check transaminases and the AST is 3x ULN, the ALT is 2x ULN.

What should you do next?

b. Identify the probable cause.
c. Follow AST, ALT, total bilirubin and alkaline phosphatase until normal.
d. All of the above.

Partly correct.

Although it is recommended that JUXTAPID treatment is discontinued in patients who experience symptoms of liver injury accompanied by elevations in transaminases. However, there are other actions that should be considered.

Review the Hepatic Monitoring Recommendations for JUXTAPID and try again.
Question 6

Sandra Brown has been on JUXTAPID for 4 months. She presents to your clinic with nausea, vomiting, abdominal pain, jaundice and is feeling “achy all over”.

You check transaminases and the AST is 3x ULN, the ALT is 2x ULN.

What should you do next?


b. **Identify the probable cause.**

c. Follow AST, ALT, total bilirubin and alkaline phosphatase until normal.

d. All of the above.

Partly correct.

Although the identification of the possible cause of the elevations in AST and ALT and the symptoms of liver injury is important, there are other actions that should be considered.

Review the Hepatic Monitoring Recommendations for JUXTAPID and try again.
Question 6

Sandra Brown has been on JUXTAPID for 4 months. She presents to your clinic with nausea, vomiting, abdominal pain, jaundice and is feeling “achy all over”.

You check transaminases and the AST is 3x ULN, the ALT is 2x ULN.

What should you do next?

b. Identify the probable cause.
c. Follow AST, ALT, total bilirubin and alkaline phosphatase.
d. All of the above.

Partly correct.

Although the AST and ALT are not higher than 3x ULN, the patient is experiencing symptoms accompanied with transaminase elevations. It is also important to follow liver functions until they resolve, however there may be other actions you should take.

Review the Hepatic Monitoring Recommendations for JUXTAPID and try again.
Question 6

Sandra Brown has been on JUXTAPID for 4 months. She presents to your clinic with nausea, vomiting, abdominal pain, jaundice and is feeling “achy all over”.

You check transaminases and the AST is 3x ULN, the ALT is 2x ULN.

What should you do next?

b. Identify the probable cause.
c. Follow AST, ALT, total bilirubin and alkaline phosphatase until normal.
d. All of the above.

Correct!

It is recommended that patients who experience elevations in transaminases accompanied by symptoms of liver injury accompanied by, discontinue treatment with JUXTAPID, LFTs should continue to be followed until they resolve, and further investigation should be instituted to identify the probable cause.
Question 7

One of the key points in the REMS program is patient education on the risks of hepatotoxicity with JUXTAPID.

a. True.
b. False.
Question 7

One of the key points in the REMS program is patient education on the risks of hepatotoxicity with JUXTAPID.

a. True.

b. False.

Correct!

JUXTAPID is associated with a risk of hepatotoxicity and as a result there is a REMS Program in place to ensure that its benefits outweigh its risks. The REMS Program requires patients to participate in the treatment decision process. This requires the prescriber to review the Guide for Patients with the patient. Knowledge of the appropriate indication for use and the risk of hepatotoxicity is expected to allow them to participate effectively in that process.
Question 7

One of the key points in the REMS program is patient education on the risks of hepatotoxicity with JUXTAPID.

a. True.
b. False.

Incorrect

Review the goals of the JUXTAPID REMS program and retry this question.
Question 8

How does a prescriber become certified in the JUXTAPID REMS Program?

a. Complete and submit the JUXTAPID REMS Program Prescriber Enrollment Form
b. Successfully complete the JUXTAPID REMS Program Prescriber Training Module and Knowledge Assessment
c. Review the JUXTAPID PI and the JUXTAPID REMS Program Fact Sheet.
d. All of the above.
Question 8

How does a prescriber become certified in the JUXTAPID REMS program?

a. Complete and submit the JUXTAPID REMS Program Prescriber Enrollment Form
b. Successfully complete the JUXTAPID REMS Program Prescriber Training Module and Knowledge Assessment
c. Review the JUXTAPID PI and the JUXTAPID REMS Fact Sheet
d. All of the above.

Almost.

To become a certified prescriber in the JUXTAPID REMS Program you must successfully complete the Prescriber Enrollment Form, Training Module and Knowledge Assessment, and review the PI and REMS Fact Sheet.

Review the Prescriber Certification Process and try again.
Question 8

How does a prescriber become certified in the JUXTAPID REMS Program?

a. Complete and submit the JUXTAPID REMS Program Prescriber Enrollment Form
b. Successfully complete the JUXTAPID REMS Prescriber Training Module and Knowledge Assessment
c. Review the JUXTAPID PI and the JUXTAPID

d. All of the above.

Almost.
To become a certified prescriber in the JUXTAPID REMS Program you must successfully complete the Prescriber Enrollment Form, Training Module and Knowledge Assessment, and review the PI and REMS Fact Sheet.

Review the Prescriber Certification Process and try again.
Question 8

How does a prescriber become certified in the JUXTAPID REMS Program?

a. Complete and submit the JUXTAPID REMS Program Prescriber Enrollment Form
b. Successfully complete the JUXTAPID REMS Program Prescriber Training Module and Knowledge Assessment
c. **Review the JUXTAPID PI and the JUXTAPID REMS Program Fact Sheet.**
d. All of the above.

If c is chosen

Almost.

To become a certified prescriber in the JUXTAPID REMS Program you must successfully complete the Prescriber Enrollment Form, Training Module and Knowledge Assessment, and review the PI and REMS Fact Sheet.

Review the Prescriber Certification Process and try again.
How does a prescriber become certified in the JUXTAPID REMS program?

a. Complete and submit the JUXTAPID REMS Program Prescriber Enrollment Form
b. Successfully complete the JUXTAPID REMS Program Prescriber Training Module and Knowledge Assessment
c. Review the JUXTAPID PI and the JUXTAPID REMS Program Fact Sheet.
d. All of the above.

Correct!

To become a certified prescriber in the JUXTAPID REMS Program you must successfully complete the prescriber enrollment form, training module and knowledge assessment, and review the PI and REMS Fact Sheet.
CONGRATULATIONS!

You have successfully completed the Prescriber Training Module and Knowledge Assessment.

Click [here](#) for a copy of your Certificate of Completion

NEXT STEPS

- Complete and sign the **Prescriber Enrollment Form**, and
- Submit the Prescriber Enrollment Form to the JUXTAPID REMS Coordinating Center either by fax: 1-855-898-2498 or email: [REMS@aegerion.com](mailto:REMS@aegerion.com)

If all the certification requirements are met, the JUXTAPID REMS Coordinating center will confirm you are certified as a prescriber in the JUXTAPID REMS Program. Once you are certified in the JUXTAPID REMS Program you can counsel patients on the REMS program requirements and prescribe JUXTAPID.
Note to Reviewer:

The following slides are the “refresher” slides that you are directed to after answering a question incorrectly. These slides are duplicates of the original slide with the exception of the hyperlink back to the question. These slides will not be visible in the training program, unless the participant answers the questions incorrectly.
JUXTAPID REMS Program Goals

The aim of the JUXTAPID REMS Program is to mitigate the risk of hepatotoxicity associated with the use of JUXTAPID by ensuring that:

1. **Prescribers are educated** about:
   - the approved indication for JUXTAPID;
   - the risk of hepatotoxicity associated with the use of JUXTAPID; and
   - the need to monitor patients during treatment with JUXTAPID as per the product labeling.

2. **JUXTAPID is dispensed only to patients with a clinical or laboratory diagnosis consistent with homozygous familial hypercholesterolemia (HoFH)**

   and

3. **Patients are informed about the risk of hepatotoxicity** associated with the use of JUXTAPID and the need for baseline and periodic monitoring.
Indication

JUXTAPID is only indicated as an adjunct to a low-fat diet and other lipid-lowering treatments including LDL apheresis, where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

Limitations of use:
- The safety and effectiveness of JUXTAPID have not been established in patients with hypercholesterolemia who do not have HoFH.
### Monitoring of transaminases

<table>
<thead>
<tr>
<th>Timing</th>
<th>Liver monitoring recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prior to initiating JUXTAPID</td>
<td>Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, and total bilirubin</td>
</tr>
</tbody>
</table>

If abnormal, consider initiating JUXTAPID only after an appropriate workup and the baseline abnormalities have been explained or resolved.

<table>
<thead>
<tr>
<th>During the first year of treatment</th>
<th>ALT and AST (at a minimum) prior to each increase in dose or monthly, whichever occurs first</th>
</tr>
</thead>
<tbody>
<tr>
<td>After the first year of treatment</td>
<td>ALT and AST (at a minimum) at least every 3 months and before any increase in dose</td>
</tr>
</tbody>
</table>

**At any time during treatment**

If transaminases are abnormal, reduce or withhold dosing of JUXTAPID and monitor as recommended in the Prescribing Information. Discontinue JUXTAPID for persistent or clinically significant elevations.

If transaminase elevations are accompanied by clinical symptoms of liver injury (such as nausea, vomiting, abdominal pain, fever, jaundice, lethargy, flu-like symptoms), increases in bilirubin ≥2x ULN, or active liver disease, discontinue treatment with JUXTAPID and identify the probable cause.
# Hepatic Monitoring Recommendations

<table>
<thead>
<tr>
<th>ALT or AST</th>
<th>Treatment and Monitoring Recommendations*</th>
</tr>
</thead>
</table>
| ≥3x and <5x ULN | • Confirm elevation with a repeat measurement within one week.  
• If confirmed, reduce the dose and obtain additional liver-related tests if not already measured (such as alkaline phosphatase, total bilirubin, and INR).  
• Repeat tests weekly and withhold dosing if there are signs of abnormal liver function (increase in bilirubin or INR), if transaminase levels rise above 5x ULN, or if transaminase levels do not fall below 3x ULN within approximately 4 weeks. In these cases of persistent or worsening abnormalities, also investigate to identify the probable cause.  
• If resuming JUXTAPID after transaminases resolve to < 3x ULN, consider reducing the dose and monitor liver-related tests more frequently. |
| ≥5x ULN | • Withhold dosing, obtain additional liver-related tests if not already measured (such as alkaline phosphatase, total bilirubin, and INR), and investigate to identify the probable cause.  
• If resuming JUXTAPID after transaminases resolve to < 3x ULN, reduce the dose and monitor liver-related tests more frequently. |

If transaminase elevations are accompanied by clinical symptoms of liver injury (such as nausea, vomiting, abdominal pain, fever, jaundice, lethargy, flu-like symptoms), increases in bilirubin ≥ 2x ULN, or active liver disease, discontinue treatment with JUXTAPID and investigate to identify the probable cause.

*Recommendations based on an ULN of approximately 30-40 international units/L
## Hepatic Monitoring Recommendations

<table>
<thead>
<tr>
<th>ALT or AST</th>
<th>Treatment and Monitoring Recommendations*</th>
</tr>
</thead>
</table>
| ≥3x and <5x ULN | - Confirm elevation with a repeat measurement within one week.  
- If confirmed, reduce the dose and obtain additional liver-related tests if not already measured (such as alkaline phosphatase, total bilirubin, and INR).  
- Repeat tests weekly and withhold dosing if there are signs of abnormal liver function (increase in bilirubin or INR), if transaminase levels rise above 5x ULN, or if transaminase levels do not fall below 3x ULN within approximately 4 weeks. In these cases of persistent or worsening abnormalities, also investigate to identify the probable cause.  
- If resuming JUXTAPID after transaminases resolve to < 3x ULN, consider reducing the dose and monitor liver-related tests more frequently. |
| ≥5x ULN | - Withhold dosing, obtain additional liver-related tests if not already measured (such as alkaline phosphatase, total bilirubin, and INR), and investigate to identify the probable cause.  
- If resuming JUXTAPID after transaminases resolve to < 3x ULN, reduce the dose and monitor liver-related tests more frequently. |

If transaminase elevations are accompanied by clinical symptoms of liver injury (such as nausea, vomiting, abdominal pain, fever, jaundice, lethargy, flu-like symptoms), increases in bilirubin ≥ 2x ULN, or active liver disease, discontinue treatment with JUXTAPID and investigate to identify the probable cause.

*Recommendations based on an ULN of approximately 30-40 international units/L

To retry Question 5, click here
# Hepatic Monitoring Recommendations

<table>
<thead>
<tr>
<th>ALT or AST</th>
<th>Treatment and Monitoring Recommendations*</th>
</tr>
</thead>
</table>
| ≥3x and <5x ULN | • Confirm elevation with a repeat measurement within one week.  
• If confirmed, reduce the dose and obtain additional liver-related tests if not already measured (such as alkaline phosphatase, total bilirubin, and INR).  
• Repeat tests weekly and withhold dosing if there are signs of abnormal liver function (increase in bilirubin or INR), if transaminase levels rise above 5x ULN, or if transaminase levels do not fall below 3x ULN within approximately 4 weeks. In these cases of persistent or worsening abnormalities, also investigate to identify the probable cause.  
• If resuming JUXTAPID after transaminases resolve to < 3x ULN, consider reducing the dose and monitor liver-related tests more frequently. |
| ≥5x ULN | • Withhold dosing, obtain additional liver-related tests if not already measured (such as alkaline phosphatase, total bilirubin, and INR), and investigate to identify the probable cause.  
• If resuming JUXTAPID after transaminases resolve to < 3x ULN, reduce the dose and monitor liver-related tests more frequently. |

If transaminase elevations are accompanied by clinical symptoms of liver injury (such as nausea, vomiting, abdominal pain, fever, jaundice, lethargy, flu-like symptoms), increases in bilirubin ≥ 2x ULN, or active liver disease, discontinue treatment with JUXTAPID and investigate to identify the probable cause.

*Recommendations based on an ULN of approximately 30-40 international units/L

[To retry Question 6 click here](#)
JUXTAPID REMS Program Goals

The aim of the JUXTAPID REMS Program is to mitigate the risk of hepatotoxicity associated with the use of JUXTAPID by ensuring that:

1. **Prescribers are educated** about:
   - the approved indication for JUXTAPID;
   - the risk of hepatotoxicity associated with the use of JUXTAPID; and
   - the need to monitor patients during treatment with JUXTAPID as per the product labeling.

2. JUXTAPID is dispensed only to patients with a clinical or laboratory diagnosis consistent with homozygous familial hypercholesterolemia (HoFH) and

3. **Patients are informed** about the risk of hepatotoxicity associated with the use of JUXTAPID and the need for baseline and periodic monitoring.

To retry Question 7 click here
Prescriber Certification Process

1. REVIEW the JUXTAPID
   - JUXTAPID Prescribing Information
   - JUXTAPID REMS Program Fact Sheet

2. COMPLETE the JUXTAPID REMS Program
   - Prescriber Training Module and Knowledge Assessment

3. AGREE to:
   - Counsel patients using the JUXTAPID REMS Program Patient Guide
   - Complete, sign and submit the JUXTAPID REMS Program Patient-Prescriber Acknowledgement Form with the patient
   - Submit a JUXTAPID REMS Program Prescription Authorization Form for each prescription

4. SUBMIT to the REMS Coordinating Center the:
   - Completed JUXTAPID REMS Program Prescriber Enrollment Form

To retry Question 8, click here
What is the JUXTAPID Risk Evaluation and Mitigation Strategy (REMS) Program?

Due to the risk of hepatotoxicity, JUXTAPID is only available through a restricted distribution program required by the US Food and Drug Administration called the JUXTAPID REMS Program.

The goal of the JUXTAPID REMS program is to mitigate the risk of hepatotoxicity associated with the use of JUXTAPID by ensuring that

1. Prescribers are educated about the approved indication for JUXTAPID, the risk of hepatotoxicity associated with the use of JUXTAPID, and the need to monitor patients during treatment with JUXTAPID as per product labeling

2. JUXTAPID is dispensed only to patients with a clinical or laboratory diagnosis consistent with HoFH

3. Patients are informed about the risk of hepatotoxicity associated with the use of JUXTAPID and the need for baseline and periodic monitoring

JUXTAPID REMS Program Requirements

- Certification of prescribers of JUXTAPID
- Patient counseling
- Certification of pharmacies to dispense JUXTAPID
- A valid JUXTAPID REMS Program Prescription Authorization Form signed by a certified prescriber, and
- A completed JUXTAPID REMS Program Patient-Prescriber Acknowledgement Form signed by the patient and a certified prescriber must be on file

Because of the risk of hepatotoxicity with the use of JUXTAPID, prescribers are recommended to monitor liver function as described in the Prescribing Information.

Please see accompanying full Prescribing Information for JUXTAPID, including BOXED WARNING for hepatotoxicity.
**Prescriber Requirements**

Only certified healthcare providers can prescribe JUXTAPID. To become certified, prescribers must:

1. **Review** the Prescribing Information, and this Fact Sheet

2. **Complete** the online JUXTAPID REMS Program Prescriber Training Module and the Prescriber Enrollment Form. Send the Prescriber Enrollment Form to the JUXTAPID REMS Coordinating Center by fax: 1-855-898-2498 or email: REMS@aegerion.com

3. **Agree**
   - To counsel each patient on the JUXTAPID REMS Program including the indication for use, the risk of hepatotoxicity and the need for monitoring using the Patient Guide
   - To complete a JUXTAPID REMS Program Patient-Prescriber Acknowledgement Form with each patient

Prescribers must also fax a JUXTAPID REMS Program Prescription Authorization Form for each prescription to the JUXTAPID REMS Program.

**Pharmacy Requirements**

Only certified pharmacies can purchase, dispense, and distribute JUXTAPID. To become certified, pharmacies must select a representative who will complete the certification process:

1. **Review** the Prescribing Information, and this Fact Sheet

2. **Complete** the online JUXTAPID REMS Program Pharmacy Training Module and the Pharmacy Enrollment Form and send it with the Certificate of Completion for the Pharmacy Training Module to the JUXTAPID REMS Coordinating Center by fax: 1-855-898-2498 or email: REMS@aegerion.com

3. **Agree** to train all relevant pharmacy staff, to implement processes and procedures to ensure prescriber certification, to be audited if necessary, and to provide prescription data

Visit [www.juxtapidREMSprogram.com](http://www.juxtapidREMSprogram.com) to access training materials and begin certification.
What is JUXTAPID?

JUXTAPID is a prescription medicine used along with a low-fat diet and other cholesterol-lowering treatments, including low-density lipoprotein apheresis where available, to lower different forms of cholesterol in people with homozygous familial hypercholesterolemia (HoFH).

Because of the risk of liver problems, JUXTAPID should only be taken by people with HoFH.

It is not known if JUXTAPID is safe and effective in people with high cholesterol who do not have HoFH, including in people who have heterozygous familial hypercholesterolemia (HeFH).

Risk of liver problems with JUXTAPID

JUXTAPID can cause liver problems such as increased liver enzymes or increased fat in the liver.

Your doctor will order blood tests to check your liver before you start JUXTAPID, if your dose is increased, and while you are taking JUXTAPID.

Blood test results will tell your doctor if certain liver enzyme levels are higher than normal. Enzyme levels higher than normal can be an early sign of liver problems. If your tests show signs of liver problems, your doctor may reduce your dose or stop JUXTAPID altogether.

There are other side effects associated with the use of JUXTAPID. Talk to your doctor about the other risks associated with JUXTAPID.

What is the JUXTAPID Risk Evaluation and Mitigation Strategy (REMS) Program?

Because of the risk of liver damage with JUXTAPID, the Food and Drug Administration (FDA) has required a special program called a Risk Evaluation and Mitigation Strategy (REMS) for JUXTAPID. The JUXTAPID REMS Program is designed to educate patients and healthcare providers about the appropriate use of JUXTAPID, the risk of liver damage when taking JUXTAPID, and the need for regular monitoring of your liver.

As part of the REMS Program, your doctor will discuss the risks of JUXTAPID with you and give you this Patient Guide.

Both you and your prescriber must sign the attached JUXTAPID REMS Program Patient-Prescriber Acknowledgement Form for you to receive JUXTAPID. Your prescriber will provide a copy of the signed form to the JUXTAPID REMS Program.

The JUXTAPID REMS Program also requires JUXTAPID to be dispensed by a REMS-certified specialty pharmacy. Your doctor will send your prescription to the certified specialty pharmacy, who will contact you if they need further information.
What do I need to do?

Before you start treatment with JUXTAPID, tell your doctor if you have had liver problems, including liver problems while taking other medicines.

While you are taking JUXTAPID, tell your doctor right away if you have any of the following symptoms, as these may be signs of liver problems:

- nausea, vomiting, or stomach pain that gets worse, changes, or does not go away
- fever
- yellowing of your eyes or skin
- feeling more tired than usual
- flu-like symptoms

JUXTAPID can cause nausea, vomiting, and stomach pain, especially if you do not eat a low-fat diet. These side effects can also be symptoms of liver problems.

Limit the amount of alcohol you drink (no more than 1 drink per day). One drink can be either a 12-ounce beer, a 5-ounce glass of wine, or 1.5 ounces of liquor.

Keep track of all the medications you are taking, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Make sure to keep your doctor and your pharmacist informed. Some medications, when taken together, can overwork the liver and cause problems.

Where can I get more information about the JUXTAPID REMS Program?

If you would like more information, talk to your doctor or visit www.juxtapidREMSprogram.com

Notes:
Instructions for Prescribers

The form must be signed by both the prescriber and patient. If the patient is under the age of 18 years, the form must be signed by their parent or legal guardian.* Fax the completed form to the JUXTAPID REMS Program at 1-855-898-2498. Provide a copy of the form to patient.

PATIENT ACKNOWLEDGEMENT

Patient First Name: ___________________________   Middle Initial: _______   Last Name: ___________________________

City: _________________________________________   State: _________   Zip: ___________________________

I have received, read, and understand the JUXTAPID REMS Program Patient Guide with my prescriber and I understand that:

• JUXTAPID is used along with diet and other lipid-lowering treatments in people with homozygous familial hypercholesterolemia (HoFH) to reduce:
  – LDL ("bad") cholesterol
  – Total cholesterol
  – A protein that carries “bad” cholesterol in the blood (apolipoprotein B)
  – Non-high-density lipoprotein cholesterol (non-HDL-C)

JUXTAPID may cause serious side effects including liver problems such as increased liver enzymes or increased fat in the liver.

• Because of these side effects, JUXTAPID is only for people with homozygous familial hypercholesterolemia (HoFH).

• I will need to have blood tests to check my liver before I start and during JUXTAPID therapy. If my tests show liver problems, my doctor may lower my dose of JUXTAPID or stop it.

Patient Signature: ___________________________________________   Date:______________________________

*Parent or Guardian Signature: ___________________________   Date:______________________________

Parent or Guardian Name: ___________________________________________

PRESCRIBER ACKNOWLEDGEMENT

Prescriber First Name: ___________________________   Middle Initial: _______   Last Name: ___________________________

Address: ________________________________________________

City: _________________________________________   State: _________   Zip: ___________________________

Office Phone: _______________________________   NPI #:____________________________

• I have counseled the patient (parent/guardian when appropriate) on the indication and risks of JUXTAPID, including the risk of liver problems, and the need for periodic monitoring.

• I have reviewed the JUXTAPID REMS Program Patient Guide with the patient (and parent/guardian when appropriate) and provided a signed copy of this form to the patient.

• I discussed all concerns and answered all questions the patient had about treatment with JUXTAPID.

Prescriber Signature: ___________________________________________   Date:______________________________
PATIENT INFORMATION

First Name: ___________________________________________ Middle Initial: ______ Last Name: ___________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________ State: ______ Zip: _________________

JUXTAPID PRESCRIPTION

Dose: ______ mg po q hs (recommended starting dosage is 5 mg daily). Quantity to dispense: __________ Refills: __________ 

Additional Instructions: ____________________________________________________________________________________________________

PRESCRIBER INFORMATION AND ATTESTATION OF REMS REQUIREMENTS

First Name: ___________________________________________ Middle Initial: ______ Last Name: ___________________________________________

Practice/Facility Name: ___________________________________________ Office Contact: ___________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________ State: ______ Zip: _________________

Office Phone: ___________________________ Office Fax: __________________________

State License #: ___________________________ NPI #: __________________________

• I understand that JUXTAPID is only indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

• I understand that JUXTAPID has not been studied in patients less than 18 years of age.

• I affirm that my patient has a clinical or laboratory diagnosis consistent with HoFH.

• I attest that I have obtained and will continue to obtain the liver-related tests for this patient as directed in the JUXTAPID Prescribing Information.
  – Prior to initiating therapy, measure ALT, AST, alkaline phosphatase, and total bilirubin.
  – During the first year, measure liver-related tests (ALT and AST at a minimum) prior to each increase in dose or monthly, whichever comes first.
  – After the first year, measure liver-related tests (ALT and AST at a minimum) at least every 3 months and before any increase in dose.

• I authorize the JUXTAPID REMS Program to act on my behalf for the limited purposes of transmitting this prescription to the appropriate pharmacy designated by the patient utilizing their benefit plan.

Prescriber Signature: ___________________________________________ ___________________________ ___________________________ Date

Substitution Permitted

Dispense as Written

REVIEW TO ENSURE ALL FIELDS ARE COMPLETED • FAX TO 1-855-898-2498

If you have any questions, please contact the JUXTAPID REMS Coordinating Center.
Dear Certified Prescriber:

Aegerion Pharmaceuticals Inc. (Aegerion) has made significant modifications to the REMS for JUXTAPID to help ensure that the benefits of treatment with JUXTAPID outweigh the risk of hepatotoxicity.

The modifications to the REMS will require all certified prescribers to be recertified in the JUXTAPID REMS Program by 2 July, 2017 by doing the following:

1. **Review:**
   - The JUXTAPID Prescribing Information (PI); and JUXTAPID REMS Program Fact Sheet (enclosed)

2. **Complete:**
   - The revised on-line JUXTAPID REMS Program Prescriber Training Module and Knowledge Assessment

3. **Agree:**
   - To counsel all patients on the JUXTAPID REMS Program using the JUXTAPID REMS Program Patient Guide and
   - To complete the JUXTAPID REMS Program Patient-Prescriber Acknowledgement Form.

4. **Submit:**
   - The JUXTAPID REMS Program Prescriber Enrollment Form and the Certificate of Completion for the Prescriber Training Module and Knowledge Assessment to the JUXTAPID REMS Coordinating Center.

*** Prescribers who do not recertify in the JUXTAPID REMS Program by 2 July 2017 will be decertified and will be unable to prescribe JUXTAPID. ***
Complete details about the modified JUXTAPID REMS Program can be found at www.juxtapidREMSProgram.com. For more information, you may also contact the JUXTAPID REMS Program toll-free at 1-85-JUXTAPID (1-855-898-2743).

Sincerely,

Pamela Foulds, M.D.
Chief Medical Officer
Aegerion Pharmaceuticals, Inc.

Attachments:
JUXTAPID REMS Program Fact Sheet
JUXTAPID Prescribing Information
The JUXTAPID® Risk Evaluation and Mitigation Strategy (REMS) Program

A REMS is a strategy to manage known or potential serious risks associated with a drug and is required by the US Food and Drug Administration (FDA) to ensure that the benefits of the drug outweigh its risks.

Aegerion Pharmaceuticals, Inc. (Aegerion) has worked with the FDA to develop the JUXTAPID REMS Program

The purpose of the JUXTAPID REMS Program is to mitigate the risk of hepatotoxicity associated with the use of JUXTAPID by ensuring that

1. Prescribers are educated about
   - The approved indication for JUXTAPID
   - The risk of hepatotoxicity associated with the use of JUXTAPID
   - The need to monitor patients during treatment with JUXTAPID, as per the product labeling

2. JUXTAPID is dispensed only to patients with a clinical or laboratory diagnosis consistent with homozygous familial hypercholesterolemia

3. Patients are informed about the risk of hepatotoxicity associated with the use of JUXTAPID and the need for baseline and periodic monitoring

Prescriber

All prescribers of JUXTAPID must become certified in the JUXTAPID REMS Program.

The 3-step process for Prescriber Certification is outlined below:

1. Review the JUXTAPID Prescribing Information and the JUXTAPID REMS Program Fact Sheet
2. Complete the online Prescriber Training Module and Prescriber Enrollment Form
3. Agree to counsel each patient using the Patient Guide, and to complete a Patient-Prescriber Acknowledgement Form with each patient

GO TO PRESCRIBER CERTIFICATION

INDICATIONS AND USAGE

Homozygous Familial Hypercholesterolemia

JUXTAPID is indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

Limitations of Use
   - The safety and effectiveness of JUXTAPID have not been established in patients with hypercholesterolemia who do not have HoFH, including those with heterozygous familial hypercholesterolemia (HeFH).
   - The effect of JUXTAPID on cardiovascular morbidity and mortality has not been determined.

For additional information about the JUXTAPID REMS Program, please call 1-855-JUXTAPID (1-855-898-2743)
Prescriber certification

To prescribe JUXTAPID®, healthcare professionals must be certified in the JUXTAPID Risk Evaluation and Mitigation Strategy (REMS) Program.

Prescriber certification is a 3-step process:

1. Review
   the Prescribing Information and Fact Sheet

2. Complete
   • the online Prescriber Training Module, including Knowledge Assessment
   • the Prescriber Enrollment Form
   • Send the Prescriber Enrollment Form to the JUXTAPID REMS Coordinating Center by fax: 1-855-898-2498 or email: REMS@aegerion.com

3. Agree
   to counsel each new patient on the risk of hepatotoxicity and the need for baseline and periodic monitoring using the Patient Guide.
   Complete a Patient-Prescriber Acknowledgement Form with each patient

For additional information about the JUXTAPID REMS Program, please call 1-85-JUXTAPID (1-855-898-2743)
Pharmacy certification

Prior to beginning certification process, please contact the JUXTAPID REMS Program, 1-855-JUXTAPID (1-855-898-2743) for consideration.

BEGIN NOW

To purchase and dispense JUXTAPID®️ all pharmacies must be certified in the JUXTAPID Risk Evaluation and Mitigation Strategy (REMS) Program. The pharmacy must identify an Authorized Representative to be certified in the JUXTAPID REMS Program. The pharmacy must be recertified if the authorized person changes.

Pharmacy certification is a 3-step process:

1. Review
   the Prescribing Information and Fact Sheet

2. Complete
   ▪️ the online Pharmacy Training Module, including Knowledge Assessment
   ▪️ the Pharmacy Enrollment Form
   ▪️ Send the Pharmacy Enrollment Form and the Certificate of Completion for the Pharmacy Training Module to the JUXTAPID REMS Coordinating Center by fax: 1-855-898-2496 or email: REMS@aegerion.com

3. Agree
   to train all relevant pharmacy staff, to implement processes and procedures to ensure prescriber certification, to be audited if necessary, and to provide prescription data

For additional information about the JUXTAPID REMS Program, please call 1-855-JUXTAPID (1-855-898-2743)
Prescriber certification is a 3-step process:

1. Review
   the Prescribing Information and Fact Sheet

2. Complete
   - the online Prescriber Training Module, including Knowledge Assessment
   - the Prescriber Enrollment Form
   - Send the Prescriber Enrollment Form to the JUXTAPID REMS Coordinating Center by fax: 1-855-896-2498 or email.

In order to complete your enrollment, you must proceed to the secure area of the Juxtapid REMS Program website.
Patient education

Risk of Liver Problems

- JUXTAPID can cause liver problems such as increased liver enzymes or increased fat in the liver.

- Because of the risk of liver problems, JUXTAPID should only be taken by people with homozygous familial hypercholesterolemia (HoFH).

- Your doctor will order blood tests to check your liver before you start taking JUXTAPID, if your dose is increased, and while you are taking JUXTAPID.

The JUXTAPID REMS Program

Because of the risk of liver damage with JUXTAPID, the Food and Drug Administration (FDA) has required a special program called a Risk Evaluation and Mitigation Strategy (REMS).

As part of the REMS Program your prescriber will discuss the risks of JUXTAPID with you, and review the Patient Guide to the REMS Program.

After reviewing the JUXTAPID REMS Program, both you and your healthcare provider will be asked to complete a form acknowledging that you understand the risks with the use of JUXTAPID.

For additional information about the JUXTAPID REMS Program, please call 1-85-JUXTAPID (1-855-898-2743)
TERMS OF USE

These Terms of Use and Website Privacy Statement ("Terms") govern the use of the Armary Pharmaceuticals Inc. and its subsidiaries (including Ayerst Pharmaceuticals Inc. ("Ayerst"); and together the "Company") website (the "Site"). ANYONE ACCESSING THE SITE AGREES TO ABIDE BY THESE TERMS.

Amaryl, Armary, and Armary Pharmaceuticals Inc. are trademarks of Amgen, Inc. and its subsidiaries (including Ayerst Pharmaceuticals Inc.). (upright "Amaryl", "we" or "us") may modify these Terms at any time, and such modification shall be effective immediately upon posting on the Site. Your continued access or use of the Site after the modifications have become effective shall be deemed your conclusive acceptance of the modified Terms.

1. License. The contents of our Site, including its "look and feel" (e.g., text, graphics, images, logo, and button icons), editorial content, notices, software (including HTML, XML-based computer programs) and other material, are protected under both United States and foreign copyright, trademark, and other laws. These contents belong to or are licensed to Armary or Ayerst. We hereby grant you the right to view and print one copy of information provided in the Site for internal use or distribution only. Permission to reprint or electronically reproduce any document or graphic in whole or in part for any other purpose is expressly prohibited, unless prior written consent is obtained from us.

2. Your Responsibility. You assume all responsibility for your use of, or access to, the Site, including your access to any Armary or Ayerst content or service obtained through the Site, and agree to indemnify, defend and hold harmless Armary and Ayerst or their respective officers, directors, employees, agents and affiliates in connection therewith.

3. Third-Party Resources On Our Site. This Site may contain links to websites operated by other parties. The linked sites are not under the control of Armary or Ayerst, and we are not responsible for the content accessible on any other Internet sites linked to this Site. Such links do not imply our endorsement of material on any other site, and Armary and Ayerst disclaims all liability with regard to your access to such linked websites. Armary and Ayerst provide links to other Internet sites as a convenience to users, and access to any other Internet sites linked to this Site is at your own risk.

4. Disclaimer. THIS SITE AND THE INFORMATION IT CONTAINS IS MADE AVAILABLE "AS IS" WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED. WE MAKE NO GUARANTEE THAT THE INFORMATION ON THIS SITE IS UP-TO-DATE, ACCURATE OR COMPLETE, AND YOU SHOULD NOT RELY ON IT FOR ANY DECISION OR TAKE ANY ACTION. WE HEREBY DISCLAIM ANY WARRANTY THAT THE INFORMATION ON THIS SITE WILL BE FREE OF INTERUPTION, OR THAT THE SITE IS FREE OF VIRUSES, WORMS, TRICIAN HORSES OR OTHER CODE THAT MANIFEST CORRUPTING OR DESTRUCTIVE PROPERTIES. Changes are periodically made to the information herein; these changes will be incorporated in new editions of the Site.

5. Indemnity. You agree to indemnify, defend and hold harmless Armary and Ayerst, and their respective officers, directors, employees, agents and affiliates from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, arising out of or relating to any violation of these Terms or any activity related to use of the Site (including but not limited to infringement of third parties' worldwide intellectual property rights or negligent or wrongful conduct) by you or any other person accessing the Site on your behalf.

6. Privacy. We do not collect personally identifying information from visitors to the Site unless you voluntarily decide to provide it to us through one of our provided e-mail addresses. Visitors are invited to make inquiries about Armary or Ayerst and our research, or to inquire about job opportunities. We will use the information you provide us in those communications to respond to your inquiry, but will not use or disclose it in any other way without your express consent, except to contractors or service providers who may provide services or perform functions on our behalf, for example, an information technology service provider or human resources consultant. Those contractors and service providers are permitted to use your personal information only for the purpose for which it has been provided and may not disclose it to any other third party except as we expressly direct and consistent with this paragraph. This paragraph applies only to information collected from visitors through the Site.

7. Copyright and Trademarks. Copyright (C) 2010 Armary Pharmaceuticals Inc. All Rights Reserved. ARMARY, ARMARY PHARMACEUTICALS, JUXTAPID, Overflow and NARGYL are trademarks and service marks of Armary Pharmaceuticals Inc. and Ayerst Pharmaceuticals Inc. trademarks and/or registered trademarks of other Armary Pharmaceuticals Inc. and Ayerst Pharmaceuticals Inc. and protected under the laws of the United States and other countries.

8. Contacting Us. To inquire about linking to the Site or about trademark or copyright matters or if you have any questions or concerns about these Terms, please contact us at doc@armarypharma.com

9. This Site Does Not Provide Medical or Professional Services Advice. The content on the Site is intended to be a general information resource in regard to the subject matter covered. Armary does not directly or indirectly practice medicine, render medical advice, or dispense medical services via the Site, and nothing contained in the Site is intended to be instruction for medical diagnosis or treatment. Any information provided should not be considered complete, nor should it be relied upon to suggest a course of treatment for a particular individual. Information received from the Site should not be relied upon for personal medical, legal, technical, or financial decisions. It should not be used in place of direct consultation with your physician or other qualified healthcare provider. Should you have any healthcare related questions, please consult with your physician or other qualified healthcare provider promptly.

10. Updates. Armary and Ayerst may make improvements and/or changes to the Site at any time. Although we attempt to periodically update information on this site, the information, materials and services provided on or through this Site may occasionally be inaccurate, incomplete or out of date. Armary and Ayerst does not have a duty to update information contained in the Site, and we will not be liable for any failure to update such information. We make no representations as to the completeness, accuracy or correctness of any information on the Site, and we undertake no obligation to update or revise the information contained on the Site. Any information you provide to us is considered confidential, unless we otherwise agree or state otherwise.

For additional information about the JUXTAPID REMS Program, please call 1-855-958-2743 (1-855-958-2743)
Aegerion Pharmaceuticals, Inc.
245 First Street, 18th Floor
Cambridge, MA 02142

For additional information about the JUXTAPID REMS Program, please call 1-85-JUXTAPID (1-855-898-2743)
Note to Reviewer:

The Juxtagid REMS Pharmacy Training and Knowledge Assessment can be accessed online by clicking the link on the website. The participant will need to register to enter the training and knowledge assessment module. The registration page requires the participant to indicate that they are an authorized representative of the pharmacy.

Participants will be required to enter their name, pharmacy name, city, state and zip code. The participant’s email address will be requested; if this is not provided the participant will be able to continue. These items will be used to generate a Certificate of Completion at the end of the program that will be required to be submitted to enroll the pharmacy in the JUXTAPID REMS program.
This interactive tool:
• Provides an overview of the JUXTAPID REMS Program
• Discusses the risk of hepatotoxicity with JUXTAPID, and
• Provides an overview of the prescriber, patient and pharmacy requirements for the JUXTAPID REMS program
To become certified to purchase, dispense and distribute JUXTAPID all pharmacies must:

- Designate an **Authorized Representative** who must:
  - **Successfully** complete this **Pharmacy Training Module & Knowledge Assessment** and print the **Certificate of Completion** at the end of the module
  - **Submit** the Certificate of Completion and the signed JUXTAPID REMS Program **Pharmacy Enrollment Form** to the JUXTAPID REMS Coordinating Center
    either by fax: 1-855-898-2498 or email: REMS@aegerion.com

At the end of the training module there is a Knowledge Assessment with interactive questions that you must pass. If your answer is incorrect you will be directed back to the relevant page in the materials and will be required to re-answer the question.

This Pharmacy training module and knowledge assessment is intended to be read in conjunction with the JUXTAPID REMS Factsheet and the JUXTAPID Prescribing Information.

This program is expected to take **10-15** minutes.

Click here to begin
Contents

- Overview of the JUXTAPID REMS Program
- Key JUXTAPID Product Information
- JUXTAPID REMS Program Information
- Knowledge Assessment
Contents

- Overview of the JUXTAPID REMS Program
- Key JUXTAPID Product Information
- JUXTAPID REMS Program Information
- Knowledge Assessment
Overview

Because of the risk of hepatotoxicity with JUXTAPID, it is only available through a restricted program called the “JUXTAPID Risk Evaluation and Mitigation Strategy (REMS) Program”.

The purpose of this training module is to educate pharmacy representatives about the JUXTAPID REMS Program including the requirements for prescribers and pharmacies.

A Risk Evaluation and Mitigation Strategy is a strategy to manage known or potential serious risks associated with a drug product and is required by the Food and Drug Administration (FDA) for some products to ensure that the benefits of the drug outweigh its risks.
JUXTAPID REMS Program Goals

The aim of the JUXTAPID REMS Program is to mitigate the risk of hepatotoxicity associated with the use of JUXTAPID by ensuring that:

1. Prescribers are educated about:
   - the approved indication for JUXTAPID;
   - the risk of hepatotoxicity associated with the use of JUXTAPID; and
   - the need to monitor patients during treatment with JUXTAPID as per the product labeling.

2. JUXTAPID is dispensed only to patients with a clinical or laboratory diagnosis consistent with homozygous familial hypercholesterolemia (HoFH)

   and

3. Patients are informed about the risk of hepatotoxicity associated with the use of JUXTAPID and the need for baseline and periodic monitoring.
Contents

- Overview of the JUXTAPID REMS Program
- Key JUXTAPID Product Information
- JUXTAPID REMS Program Information
- Knowledge Assessment
Indication

JUXTAPID is indicated as an adjunct to a low-fat diet and other lipid-lowering treatments including LDL apheresis, where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

Limitations of use Related to the REMS:

- The safety and effectiveness of JUXTAPID have not been established in patients with hypercholesterolemia who do not have HoFH, including those with heterozygous familial hypercholesterolemia (HeFH).

Please see JUXTAPID full Prescribing Information for the limitations to use, and the BOXED WARNING on hepatotoxicity as included on www.juxtapidREMSprogram.com
Appropriate Patient Selection

JUXTAPID is only indicated for use in patients with HoFH.
• Patients must have a clinical or laboratory diagnosis consistent with HoFH.

Related Contraindications:
• Moderate or severe hepatic impairment or active liver disease including unexplained persistent abnormal liver function tests.

Please see JUXTAPID full Prescribing Information for the limitations to use, and the BOXED WARNING on hepatotoxicity as included on www.juxtapidREMSprogram.com
Boxed Warning – Risk of Hepatotoxicity

JUXTAPID can cause elevations in transaminases. In the JUXTAPID clinical trial, 10 (34%) of the 29 patients treated with Juxtapid had at least one elevation in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 3x upper limit of normal (ULN). There were no concomitant clinically meaningful elevations of total bilirubin, international normalized ratio (INR), or alkaline phosphatase.

JUXTAPID also increases hepatic fat, with or without concomitant increases in transaminases. The median absolute increase in hepatic fat was 6% after both 26 and 78 weeks of treatment, from 1% baseline, measured by magnetic resonance spectroscopy. Hepatic steatosis associated with JUXTAPID treatment may be a risk factor for progressive liver disease, including steatohepatitis and cirrhosis.

Measure ALT, AST, alkaline phosphatase, and total bilirubin before initiating treatment and then ALT and AST regularly as recommended. During treatment adjust dose of JUXTAPID if the ALT or AST are ≥ 3x ULN. Discontinue JUXTAPID for clinical significant liver toxicity.

Please see JUXTAPID full Prescribing Information including the full BOXED WARNING as included on www.juxtapidREMSprogram.com
Risk of Hepatotoxicity: JUXTAPID can Cause Elevations in Transaminases

Although cases of hepatic failure have not been reported, there is concern that JUXTAPID could induce steatohepatitis, which can progress to cirrhosis over several years.

Elevations in transaminases (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST]) are associated with JUXTAPID. In the clinical trial, 10 (34%) of the 29 patients with HoFH had at least one elevation in ALT or AST ≥3x ULN, and 4 (14%) of the patients had at least one elevation in ALT or AST ≥5x ULN. There were no concomitant or subsequent clinically meaningful elevations in bilirubin, INR, or alkaline phosphatase.

If transaminase elevations are accompanied by clinical symptoms of liver injury, such as nausea, vomiting, abdominal pain, fever, jaundice, lethargy, flu-like symptoms, increases in bilirubin ≥ 2x ULN, or active liver disease, discontinue treatment with JUXTAPID and identify the probable cause.
JUXTAPID increases hepatic fat, with or without concomitant increases in transaminases.

The median absolute increase in hepatic fat was 6% after both 26 and 78 weeks of treatment, from 1% baseline, measured by magnetic resonance spectroscopy. Hepatic steatosis associated with JUXTAPID treatment may be a risk factor for progressive liver disease, including steatohepatitis and cirrhosis.

Clinical data suggest that hepatic fat accumulation is reversible after stopping treatment with JUXTAPID, but whether histological sequelae remain is unknown.
Contents

- Overview of the JUXTAPID REMS Program
- Key JUXTAPID Product Information
- JUXTAPID REMS Program Information
- Knowledge Assessment
JUXTAPID REMS Program Goals

The aim of the JUXTAPID REMS Program is to mitigate the risk of hepatotoxicity associated with the use of JUXTAPID by ensuring that:

1. **Prescribers are educated** about:
   - the approved indication for JUXTAPID;
   - the risk of hepatotoxicity associated with the use of JUXTAPID; and
   - the need to monitor patients during treatment with JUXTAPID as per the product labeling.

2. JUXTAPID is **dispensed only to patients with a clinical or laboratory diagnosis consistent with homozygous familial hypercholesterolemia (HoFH)**
   and

3. **Patients are informed about the risk of hepatotoxicity** associated with the use of JUXTAPID and the need for baseline and periodic monitoring.
Prescribers must be certified to prescribe JUXTAPID

Patients must undergo education about the REMS program the approved indication for use the risk of hepatotoxicity with JUXTAPID and the need for regular monitoring

Pharmacies must be certified to distribute and dispense JUXTAPID
Patient-Prescriber Acknowledgment

To enable **patient participation** in the treatment decision process both patients and prescribers are required to review and complete the patient-prescriber acknowledgement form. This form is attached to the Guide for Patients and must be submitted to the JUXTAPID REMS Coordinating Center for all new patients.

**THE PRESCRIBER:**

1. **REVIEWS** the
   - JUXTAPID REMS Program Patient Guide with the patient.
   This document provides a summary of JUXTAPID and the REMS program requirements.

2. **COMPLETES** the:
   - JUXTAPID REMS Program Patient-Prescriber Acknowledgement Form (PPAF)
   The PPAF is signed by both the patient and the prescriber and acknowledges that the patient has received education on the JUXTAPID REMS program, understands the hepatic risk and the need for regular monitoring.

**Prescriptions will not be dispensed without a completed PPAF on record**
Pharmacy Certification Process
Authorized Representative Requirements

For a Pharmacy to be certified in the JUXTAPID REMS Program, the pharmacy must designate an Authorized Representative (AR).

The Authorized Representative is required to:

- **Complete** the pharmacy training module and knowledge assessment,
- **Oversee** the conduct of the JUXTAPID REMS at the pharmacy,
- **Agree** to put processes in place, and to **train** applicable pharmacy staff on the JUXTAPID REMS program requirements.

The pharmacy must confirm the name of the authorized representative every year, and advise the REMS Coordinating Center promptly of any change in the AR. If the AR changes, the Pharmacy must recertify within 30 days.
Pharmacy Certification Process

The Authorized Representative must:

1. REVIEW the
   - JUXTAPID Prescribing Information (PI)
   - JUXTAPID REMS Program Fact Sheet

2. COMPLETE the:
   - JUXTAPID REMS Program Pharmacy Training Module and Knowledge Assessment

3. AGREE to:
   - Train all applicable pharmacy staff on the JUXTAPID REMS program requirements.
   - Implement processes and procedures to ensure that the requirements of the REMS are met
   - Be audited.
   - Provide prescription records to Aegerion.

4. SUBMIT to the REMS Coordinating Center the:
   - Certificate of Completion for the Pharmacy Training & Knowledge Assessment.
   - Completed JUXTAID REMS Program Pharmacy Enrollment Form.
The Pharmacy Must Agree to put Procedures in Place to Verify Prior to Dispensing:

1. The **Prescriber** is **Certified**.

2. There is a completed and signed **JUXTAPID REMS Program Patient-Prescriber Acknowledgement Form** for the patient.

3. The JUXTAPID REMS Program **Prescription Authorization Form** is completed.
Where do I find the REMS Program Materials?

All JUXTAPID REMS Program materials can be found on the JUXTAPID REMS Program website:

www.juxtapidREMSprogram.com

REMS Materials can also be requested by contacting the JUXTAPID REMS Coordinating Center at:

📞 1-855-898-2743
Knowledge Assessment
Question 1

The goals of the JUXTAPID REMS program are:
(check the answer that is the most inclusive)

☐ To educate prescribers about the risk of hepatotoxicity with the use of JUXTAPID.
☐ To restrict the use of JUXTAPID to only those patients with a clinical and laboratory diagnosis of HoFH.
☐ To ensure both prescribers and patients understand the risk of hepatotoxicity with JUXTAPID and the need for monitoring of liver function.
☐ All of the above.
Question 1

The goals of the JUXTAPID REMS program are:
(check the answer that is the most inclusive)

☐ To educate prescribers about the risk of hepatotoxicity with the use of JUXTAPID.

☐ To restrict the use of JUXTAPID to only those patients with a clinical and laboratory diagnosis of HoFH.

☐ To ensure both prescribers and patients understand the risk of hepatotoxicity with JUXTAPID and the need for monitoring of liver function.

☐ All of the above.

Partly correct

The education of prescribers about the risk of hepatotoxicity with the use of JUXTAPID is a key part of the JUXTAPID REMS Program. However, there are other goals too. Review the REMS Program goals and try again.
Question 1

The goals of the JUXTAPID REMS program are:
(check the answer that is the most inclusive)

☐ To educate prescribers about the risk of hepatotoxicity with the use of JUXTAPID.
☐ To restrict the use of JUXTAPID to only those patients with a clinical and laboratory diagnosis of HoFH.
☐ To ensure both prescribers and patients understand the risk of hepatotoxicity with JUXTAPID and the need for monitoring of liver function.
☐ All of the above.

Partly correct

The restriction of the use of JUXTAPID to patients with a clinical or laboratory diagnosis of HoFH is a key part of the JUXTAPID REMS Program. However, there are other goals too. Review the REMS Program goals and try again.
Question 1

The goals of the JUXTAPID REMS program are:
(check the answer that is the most inclusive)

☐ To educate prescribers about the risk of hepatotoxicity with the use of JUXTAPID.
☐ To restrict the use of JUXTAPID to only those patients with a clinical and laboratory diagnosis of HoFH.
☐ To ensure both prescribers and patients understand the risk of hepatotoxicity with JUXTAPID and the need for monitoring of liver function.
☐ All of the above.

Partly correct

The education of both prescribers and patients about the risk of hepatotoxicity with JUXTAPID and the need for monitoring is an important part of the JUXTAPID REMS Program. However, there are other goals. Review the REMS Program goals and try again.
The goals of the JUXTAPID REMS program are:
(check the answer that is the most inclusive)

☐ To educate prescribers about the risk of hepatotoxicity with the use of JUXTAPID.
☐ To restrict the use of JUXTAPID to only those patients with a clinical and laboratory diagnosis of HoFH.
☐ To ensure both prescribers and patients understand the risk of hepatotoxicity with JUXTAPID and the need for monitoring of liver function.
☐ All of the above.

Correct!
All three are goals of the JUXTAPID REMS Program.
Question 2

Which conditions are appropriate for the use of JUXTAPID?

a. Mixed dyslipidemia.
b. Homozygous familial hypercholesterolemia (HoFH).
c. Heterozygous familial hypercholesterolemia (HeFH).
d. All of the above.
Question 2

Which conditions are appropriate for the use of JUXTAPID?

a. Mixed dyslipidemia.
b. Homozygous familial hypercholesterolemia (HoFH).
c. Heterozygous familial hypercholesterolemia (HeFH).
d. All of the above.

Incorrect

JUXTAPID is indicated for use in patients with homozygous familial hypercholesterolemia (HoFH).

Review the Indication for JUXTAPID and try again.
Question 2

Which conditions are appropriate for the use of JUXTAPID?

a. Mixed dyslipidemia.

b. Homozygous familial hypercholesterolemia (HoFH).

c. Heterozygous familial hypercholesterolemia (HeFH).

d. All of the above.

Correct!

JUXTAPID is indicated for use as an adjunct to a low-fat diet and other lipid-lowering treatments including LDL apheresis, where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).
Question 2

Which conditions are appropriate for the use of JUXTAPID?

a. Mixed dyslipidemia  
b. Homozygous familial hypercholesterolemia (HoFH)  
c. Heterozygous familial hypercholesterolemia (HeFH)  
d. All of the above

Incorrect

JUXTAPID is indicated for use in patients with homozygous familial hypercholesterolemia (HoFH).

Review the Indication for JUXTAPID and try again.
Question 2

Which conditions are appropriate for the use of JUXTAPID?

a. Mixed dyslipidemia.
b. Homozygous familial hypercholesterolemia (HoFH).
c. Heterozygous familial hypercholesterolemia (HeFH).
d. All of the above.

Incorrect

JUXTAPID is indicated for use in patients with homozygous familial hypercholesterolemia (HoFH).

Review the Indication for JUXTAPID and try again.
Question 3

One of the key points in the REMS program is patient education on the risks of hepatotoxicity with JUXTAPID.

a. True
b. False
Question 3

One of the key points in the REMS program is patient education on the risks of hepatotoxicity with JUXTAPID.

a. True
b. False

Correct!

JUXTAPID is associated with a risk of hepatotoxicity and as a result there is a REMS Program in place to ensure that its benefits outweigh its risks. The REMS Program requires patients to participate in the treatment decision process. Knowledge of the risk of hepatotoxicity is expected to allow them to participate effectively in that process.
Question 3

One of the key points in the REMS program is patient education on the risks of hepatotoxicity with JUXTAPID.

a. True
b. False

Incorrect

Review the goals of the JUXTAPID REMS program and retry this question.
Question 4

How does a pharmacy become certified in the JUXTAPID REMS program?

a. Complete and submit the JUXTAPID REMS Program Pharmacy Enrollment Form.
b. Successfully complete the JUXTAPID REMS Program Pharmacy Training Module and Knowledge Assessment and then submit the Certificate of Completion.
c. Review the JUXTAPID PI and the JUXTAPID REMS Program Factsheet.
d. Assign an authorized representative.
e. All of the above.
Question 4

How does a pharmacy become certified in the JUXTAPID REMS program?

a. Complete and submit the JUXTAPID REMS Program Pharmacy Enrollment Form.
b. Successfully complete the JUXTAPID REMS Program Pharmacy Training Module and Knowledge Assessment and then submit the Certificate of Completion.
c. Review the JUXTAPID PI and the JUXTAPID REMS Program Factsheet.
d. Assign an authorized representative.
e. All of the above.

Partly Correct.

To become a certified pharmacy in the JUXTAPID REMS Program you must assign an authorized representative for the pharmacy, who completes the enrollment form, training module and knowledge assessment, and reviews the JUXTAPID PI and JUXTAPID REMS Program Factsheet. The Authorized Representative must agree on behalf of the pharmacy to put processes and procedures in place and to train the pharmacy staff on the JUXTAPID REMS Program.

Review the Pharmacy Certification Process and try again.
How does a pharmacy become certified in the JUXTAPID REMS program?

a. Complete and submit the JUXTAPID REMS Program Pharmacy Enrollment Form.
b. **Successfully complete the JUXTAPID REMS Program Pharmacy Training Module and Knowledge Assessment and then submit the Certificate of Completion.**
c. Review the JUXTAPID PI and the JUXTAPID REMS Program Factsheet.
d. Assign an authorized representative.
e. All of the above.

Partly Correct

To become a certified pharmacy in the JUXTAPID REMS Program you must assign an authorized representative for the pharmacy, who completes the enrollment form, training module and knowledge assessment, and reviews the JUXTAPID PI and JUXTAPID REMS Program Factsheet. The Authorized Representative must agree on behalf of the pharmacy to put processes and procedures in place and to train the pharmacy staff on the JUXTAPID REMS Program.

Review the [Pharmacy Certification Process](#) and try again.
Question 4

How does a pharmacy become certified in the JUXTAPID REMS program?

a. Complete and submit the JUXTAPID REMS Program Pharmacy Enrollment Form.
b. Successfully complete the JUXTAPID REMS Program Pharmacy Training Module and Knowledge Assessment and then submit the Certificate of Completion.
c. Review the JUXTAPID PI and the JUXTAPID REMS Program Factsheet.
d. Assign an Authorized Representative.
e. All of the above.

Partly Correct

To become a certified pharmacy in the JUXTAPID REMS Program you must assign an authorized representative for the pharmacy, who completes the enrollment form, training module and knowledge assessment, and reviews the JUXTAPID PI and JUXTAPID REMS Program Factsheet. The Authorized Representative must agree on behalf of the pharmacy to put processes and procedures in place and to train the pharmacy staff on the JUXTAPID REMS Program.

Review the Pharmacy Certification Process and try again.
Question 4

How does a pharmacy become certified in the JUXTAPID REMS program?

a. Complete and submit the JUXTAPID REMS Program Pharmacy Enrollment Form.
b. Successfully complete the JUXTAPID REMS Program Pharmacy Training Module and Knowledge Assessment and then submit the Certificate of Completion.
c. Review the JUXTAPID PI and the JUXTAPID REMS Program Factsheet.
d. Assign an Authorized Representative.
e. All of the above.

Partly Correct

To become a certified pharmacy in the JUXTAPID REMS Program you must assign an authorized representative for the pharmacy, who completes the enrollment form, training module and knowledge assessment, and reviews the JUXTAPID PI and JUXTAPID REMS Program Factsheet. The Authorized Representative must agree on behalf of the pharmacy to put processes and procedures in place and to train the pharmacy staff on the JUXTAPID REMS Program.

Review the Pharmacy Certification Process and try again.
Question 4

How does a pharmacy become certified in the JUXTAPID REMS program?

a. Complete and submit the JUXTAPID REMS Program Pharmacy Enrollment Form.
b. Successfully complete the JUXTAPID REMS Program Pharmacy Training Module and Knowledge Assessment and then submit the Certificate of Completion.
c. Review the JUXTAPID PI and the JUXTAPID REMS Program Factsheet.
d. Assign an Authorized Representative.
e. All of the above.

Correct!

To become a certified pharmacy in the JUXTAPID REMS Program you must assign an authorized representative for the pharmacy, who completes the enrollment form, training module and knowledge assessment, and reviews the JUXTAPID PI and JUXTAPID REMS Program Factsheet. The Authorized Representative must agree on behalf of the pharmacy to put processes and procedures in place and to train the pharmacy staff on the JUXTAPID REMS Program.
Question 5

What is **not** a requirement of the Authorized Pharmacy Representative?

a) Review the JUXTAPID REMS Program Fact Sheet
b) Oversee the conduct of the JUXTAPID REMS at the Pharmacy
c) Complete the JUXTAPID REMS Program Patient-Prescriber Acknowledgement Form
d) Put processes and procedures in place to ensure the JUXTAPID REMS Program requirements are met
Question 5

What is not a requirement of the Authorized Pharmacy Representative?

a) Review the JUXTAPID Prescribing Information and the JUXTAPID REMS Program Fact Sheet

b) Oversee the conduct of the JUXTAPID REMS at the Pharmacy

c) Complete the JUXTAPID REMS Program Patient-Prescriber Acknowledgement Form

d) Put processes and procedures in place to ensure the JUXTAPID REMS Program requirements are met

Incorrect.
The Authorized Representative of the Pharmacy is required to review the JUXTAPID REMS Program Factsheet and Prescribing Information, oversee the conduct of the REMS, and to put processes and procedures in place to ensure the REMS requirements are met at the pharmacy.

The Prescriber and the Patient must complete the Patient-Prescriber Acknowledgement Form, which must be kept on file for all patients. Review the Authorized Representative Requirements and try again.
Question 5

What is **not** a requirement of the Authorized Pharmacy Representative?

a) Review the JUXTAPID Prescribing Information and the JUXTAPID REMS Program Fact Sheet

b) **Oversee the conduct of the JUXTAPID REMS at the Pharmacy**

c) Complete the JUXTAPID REMS Program Patient-Prescriber Acknowledgement Form

d) Put processes and procedures in place to ensure the JUXTAPID REMS Program requirements are met

**In correct.**

The Authorized Representative of the Pharmacy **is** required to review the JUXTAPID REMS Program Factsheet and Prescribing Information, oversee the conduct of the REMS, and to put processes and procedures in place to ensure the REMS requirements are met at the pharmacy.

The Prescriber and the Patient must complete the Patient-Prescriber Acknowledgement Form, which must be kept on file for all patients.

Review the [Authorized Representative Requirements](#) and try again.
Question 5

What is **not** a requirement of the Authorized Pharmacy Representative?

a) Review the JUXTAPID Prescribing Information and the JUXTAPID REMS Program Fact Sheet

b) Oversee the conduct of the JUXTAPID REMS at the Pharmacy

c) **Complete the JUXTAPID REMS Program Patient-Prescriber Acknowledgement Form**

d) Put processes and procedures in place to ensure requirements are met

*Correct!*

The Prescriber and the Patient must complete the Patient-Prescriber Acknowledgement Form, not the pharmacy authorized representative, however, the Patient Prescriber Acknowledgement form must be kept on file at the pharmacy for all patients.
Question 5

What is **not** a requirement of the Authorized Pharmacy Representative?

a) Review the JUXTAPID Prescribing Information and the JUXTAPID REMS Program Fact Sheet

b) Oversee the conduct of the JUXTAPID REMS Program

c) Complete the JUXTAPID REMS Program Patient-Prescriber Acknowledgement Form

d) Put processes and procedures in place to ensure the requirements are met

**Incorrect.**
The Authorized Representative of the Pharmacy is required to review the JUXTAPID REMS Program Factsheet and Prescribing Information, oversee the conduct of the REMS, and to put processes and procedures in place to ensure the REMS requirements are met at the pharmacy.

The Prescriber and the Patient must complete the Patient-Prescriber Acknowledgement Form, which must be kept on file for all patients.

Review the [Authorized Representative Requirements](#) and try again.
CONGRATULATIONS!

You have successfully completed the Pharmacy Representative Training Module and Knowledge Assessment.

Click [here](#) for a copy of your Certificate of Completion

**NEXT STEPS**

- Obtain the **Certificate of Completion** for the Pharmacy Training & Knowledge Assessment
- Complete and sign the **Pharmacy Enrollment Form**, and
- Submit both documents to the JUXTAPID REMS Coordinating Center either by fax: 1-855-898-2498 or email: [REMS@aegerion.com](mailto:REMS@aegerion.com)

If all the certification requirements are met, the JUXTAPID REMS Coordinating center will confirm you are certified as a pharmacy in the JUXTAPID REMS Program.
Note to Reviewer:

The following slides are the “refresher” slides that you are directed to after answering a question incorrectly. These slide are duplicates of the original slide with the exception of the hyperlink back to the question. These slide will not be visible in the training program, unless the participant answers the questions incorrectly.
JUXTAPID REMS Program Goals

The aim of the JUXTAPID REMS Program is to mitigate the risk of hepatotoxicity associated with the use of JUXTAPID by ensuring that:

1. **Prescribers are educated** about:
   - the approved indication for JUXTAPID;
   - the risk of hepatotoxicity associated with the use of JUXTAPID; and
   - the need to monitor patients during treatment with JUXTAPID as per the product labeling.

2. **JUXTAPID is dispensed only to patients with a clinical or laboratory diagnosis consistent with homozygous familial hypercholesterolemia (HoFH)**

   and

3. **Patients are informed about the risk of hepatotoxicity** associated with the use of JUXTAPID and the need for baseline and periodic monitoring.

To retry Question 1 click here
Indication

JUXTAPID is indicated as an adjunct to a low-fat diet and other lipid-lowering treatments including LDL apheresis, where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

Limitations of use:

- The safety and effectiveness of JUXTAPID have not been established in patients with hypercholesterolemia who do not have HoFH.
JUXTAPID REMS Program Goals

The aim of the JUXTAPID REMS Program is **to mitigate the risk of hepatotoxicity associated with the use of JUXTAPID** by ensuring that:

1. **Prescribers are educated** about:
   - the approved indication for JUXTAPID;
   - the risk of hepatotoxicity associated with the use of JUXTAPID; and
   - the need to monitor patients during treatment with JUXTAPID as per the product labeling.

2. JUXTAPID is **dispensed only to patients with a clinical or laboratory diagnosis consistent with homozygous familial hypercholesterolemia (HoFH)** and

3. **Patients are informed about the risk of hepatotoxicity** associated with the use of JUXTAPID and the need for baseline and periodic monitoring.
Pharmacy Certification Process

1. REVIEW the
   - JUXTAPID Prescribing Information (PI)
   - JUXTAPID REMS Program Fact Sheet

2. COMPLETE the:
   - JUXTAPID REMS Program Pharmacy Training Module and Knowledge Assessment

3. AGREE to:
   - Train all applicable pharmacy staff on the JUXTAPID REMS program requirements
   - Implement processes and procedures to ensure that the requirements of the REMS are met
   - Be audited.
   - Provide prescription records to Aegerion.

4. SUBMIT to the REMS Coordinating Center the:
   - Certificate of Completion for the Pharmacy Training & Knowledge Assessment
   - Completed JUXTAPID REMS Program Pharmacy Enrollment Form

For a Pharmacy to be Certified the Pharmacy must designate an Authorized Representative (AR) who will be required to complete the pharmacy training module and knowledge assessment, oversee the conduct of the REMS at the pharmacy and agree to put processes in place and to train applicable pharmacy staff on the REMS program requirements.

The Pharmacy must confirm the name of the authorized representative every year, and advise the REMS coordinating center promptly of any change in the AR. If the AR changes, the Pharmacy must recertify within 30 days.

Redirect from Question 4
To retry Question 4 click here
Authorized Representative Requirements

For a Pharmacy to be certified in the JUXTAPID REMS Program, the pharmacy must designate an Authorized Representative (AR).

The Authorized Representative is required to:

• **Complete** the *pharmacy training module* and knowledge assessment,
• **Oversee** the *conduct of the JUXTAPID REMS* at the pharmacy,
• **Agree** to put *processes* in place, and to *train* applicable pharmacy staff on the JUXTAPID REMS program requirements.

The pharmacy must confirm the name of the authorized representative every year, and advise the REMS Coordinating Center promptly of any change in the AR. If the AR changes, the Pharmacy must recertify within 30 days.
JUXTAPID is only available through the JUXTAPID Risk Evaluation and Mitigation Strategy (REMS) Program. In order to become certified and purchase, dispense and distribute JUXTAPID, pharmacies must agree to 1) recertify if there is a change in the authorized representative 2) be audited 3) provide prescription data to Aegerion as requested.

As the Authorized Pharmacy Representative, I attest that:

- I have reviewed the Prescribing Information (PI) for JUXTAPID
- I have reviewed the JUXTAPID REMS Program Fact Sheet that summarizes the risks and requirements of the JUXTAPID REMS program
- I have completed the JUXTAPID REMS Program Pharmacy Training Module including the Knowledge Assessment component
- I agree to train all pharmacy staff involved with JUXTAPID in the requirement of the REMS Program.

Authorized Pharmacy Representative Attestation
I agree to put processes and procedures in place to verify, prior to dispensing JUXTAPID® (lomitapide) capsules, that:

– The prescriber is certified in the JUXTAPID REMS Program
– The JUXTAPID REMS Program Prescription Authorization Form is received for each new prescription
– The JUXTAPID REMS Program Patient-Prescriber Acknowledgement Form is on file with the JUXTAPID REMS Program Coordinating Center

Signature: ___________________________________________ Date: __________________________

This form must be completed for initial pharmacy enrollment, re-certification and after any changes with the authorized representative.
PHARMACY ACTION NEEDED

Subject: Significant Modifications to the JUXTAPID® (lomitapide) capsules Risk Evaluation and Mitigation Strategy (REMS) Program

Pharmacy Action: Recertification Required by 2 July, 2017

Dear Certified Pharmacy:

Aegerion Pharmaceuticals Inc. (Aegerion) has made significant modifications to the REMS for JUXTAPID to help ensure that the benefits of treatment with JUXTAPID outweigh the risk of hepatotoxicity.

The modifications to the REMS will require all certified pharmacies to be recertified in the JUXTAPID REMS Program by 2 July, 2017 by doing the following:

1. Designate an Authorized Representative who will be required to:

   a. **Review** the JUXTAPID:
      
      • Prescribing Information (PI); and JUXTAPID REMS Program Fact Sheet (enclosed)

   b. **Successfully complete**:
      
      • The on-line JUXTAPID REMS Program Pharmacy Training Module and Knowledge Assessment

   c. **Agree** to:
      
      • Train all applicable pharmacy staff on the JUXTAPID REMS program requirements.
      • Implement processes and procedures to ensure that the requirements of the JUXTAPID REMS Program are met.
      • Be audited.
      • Provide prescription records to Aegerion.

2. **Submit**:

   • The JUXTAPID REMS Program Pharmacy Enrollment Form and the Certificate of Completion for the JUXTAPID REMS Program Pharmacy Training Module and Knowledge Assessment to the JUXTAPID REMS Coordinating Center.

*** Pharmacies who do not recertify in the JUXTAPID REMS Program by 2 July, 2017 will be decertified and will be unable to purchase, dispense or distribute JUXTAPID ***
Complete details about the modified JUXTAPID REMS Program can be found at www.JUXTAPIDREMSProgram.com. For more information, you may also contact the JUXTAPID REMS Program toll-free at 1-85-JUXTAPID (1-855-898-2743).

Sincerely,

Pamela Foulds, M.D.
Chief Medical Officer
Aegerion Pharmaceuticals, Inc.

Attachments:
JUXTAPID REMS Program Fact Sheet
JUXTAPID Prescribing Information